Lauren Averett Byers, M.D.

Peer-Reviewed Articles

1. Li H, Hong L, Rocha P, Bach R, Solis Soto LM, Rinsurongkawong W, Zhang B, Araujo HA, Elamin YY, Altan M, Arrechedera CA, Zhou J, Khan KB, Lu W, Young E, Gay CM, Cascone T, Byers LA, Skoulidis F, Blumenschein G, Fossella FV, Tsao A, Negrao MV, Vokes N, Wu J, Tran HT, Wistuba II, Lee J, Gibbons DL, Vaporciyan AA, Heymach JV, Le X, Zhang J. MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer. Cancers, 2025. e-Pub 2025.
2. Stewart CA, Ramkumar K, Wang R, Xi Y, Halliday A, Diao L, Wang Q, Serrano A, Groves S, Heeke S, Tanimoto A, Kaiser L, Lewis W, Bose M, Da Rocha P, Karacosta L, Quaranta V, Wang J, George J, Solis Soto LM, Zhang B, Heymach JV, Byers LA, Gay CM. YAP1 defines an emergent, plastic population of relapsed small cell lung cancer. bioRxiv, 2025. e-Pub 2025. PMID: 41279637.
3. Aminu M, Zhu B, Vokes N, Chen H, Hong L, Li J, Fujimoto J, Chaib M, Yang Y, Wang B, Poteete A, Nilsson MB, Le X, Cascone T, Jaffray D, Navin N, Wang T, Byers LA, Gibbons DL, Heymach J, Chen K, Cheng C, Zhang J, Wu J. CoCo-ST detects global and local biological structures in spatial transcriptomics datasets. Nat Cell Biol, 2025. e-Pub 2025. PMID: 41083603.
4. Cooper AJ, Herzberg B, Parma M, Wang K, Alder L, Weber UM, Patil T, Joshi U, Puri S, Saqi A, Clark P, Gay CM, Cascone T, Singhi EK, Blumenschein G, Skoulidis F, Tu J, Stinchcombe TE, Rudin CM, Shu CA, Byers LA, Yu H, Zhang B. Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR-Mutant Transformed Small Cell Lung Cancer. JCO Precis Oncol 9:e2500538, 2025. e-Pub 2025. PMID: 41166675.
5. Owonikoko TK, Byers L, Cheng Y, Hayashi H, Paz-Arese L, Pérol M, Hu H, Qianh M, Garciah CR, Godardi J, Tangh M, Rudin CM. IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer. Future Oncol, 2025. e-Pub 2025. PMID: 41055143.
6. Ciardullo C, Tobalina L, Carr TH, Szekeres P, Kraljevic S, Byers LA, Fabbri G. Early ctDNA dynamics inform first-line therapy in patients with extensive-stage small cell lung cancer. Clin Cancer Res, 2025. e-Pub 2025. PMID: 40788282.
7. Galan-Cobo A, Vokes NI, Qian Y, Molkentine D, Ramkumar K, Paula AG, Pisegna M, McGrail DJ, Poteete A, Cho S, Do MT, Karimi A, Kong Y, Solanki A, Karmokar A, Floc'h N, Hughes A, Sargeant R, Young L, Shen L, Kar G, Keshvani C, Arrechedera C, Hernandez S, Schlacher K, Wang J, Iyer S, Conway J, Keddar MR, Milo M, de Toma I, Critchlow SE, Barrett JC, Cosaert J, Lau A, Valge-Archer V, Byers LA, Barry ST, Heymach JV. KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. Cancer Cell, 2025. e-Pub 2025. PMID: 40645185.
8. Gay CM, Owonikoko TK, Byers LA, Choudhury NJ, Ahmed S, Cain Z, Qian X, Brentnall M, Heeke S, Poi M, Wu S, Rudin CM. Multidimensional Analysis of B7 homolog 3 (B7-H3) RNA Expression in Small-cell Lung Cancer Molecular Subtypes. Clin Cancer Res, 2025. e-Pub 2025. PMID: 40553459.
9. Heeke, S, Gandhi, S, Tran, HT, Lam, VK, Byers, LA, Gibbons, DL, Gay, CM, Altan, M, Antonoff, MB, Le, X, Tu, J, Saad, M, Pek, M, Poh, J, Ngeow, KC, Tsao, A, Cascone, T, Vailati Negrao, M, Wu, J, Blumenschein, GR, Heymach, JV, Elamin, YY. Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA. JTO Clinical and Research Reports 6(4), 2025. e-Pub 2025. PMID: 40160974.
10. De Rosa C, Morgillo F, Amato L, Iommelli F, De Rosa V, Tirino V, Papaccio F, Tuccillo C, Di Guida G, D'Angiolella DM, Di Liello A, Zappavigna S, Caraglia M, Gambardella A, Nardone V, Ramkumar K, Wang Q, Wang J, De Vita F, Ciardiello D, Martinelli E, Troiani T, Napolitano S, Martini G, Servetto A, Byers LA, Ciardiello F, Della Corte CM. DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer. iScience 28(3):111943, 2025. e-Pub 2025. PMID: 40034862.
11. Morris, BB, Heeke, S, Xi, Y, Diao, L, Wang, Q, Rocha, P, Arriola, E, Lee, MC, Tyson, DR, Concannon, KF, Ramkumar, K, Stewart, CA, Cardnell, R, Wang, R, Quaranta, V, Wang, J, Heymach, JV, Nabet, BY, Shames, DS, Gay, CM, Byers, LA. DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer. Molecular cancer 24(1), 2025. e-Pub 2025. PMID: 40114214.
12. Meric-Bernstam F, Yuca E, Evans KW, Zhao M, Maejima T, Karibe T, Raso MG, Tang X, Zheng X, Rizvi YQ, Akcakanat A, Scott SS, Wang B, Byers LA, Tripathy D, Okajima D, Damodaran S. Anti-tumor activity and biomarker analysis for TROP2-antibody drug conjugate Datopotamab deruxtecan in patient-derived breast cancer xenograft models. Clin Cancer Res, 2024. e-Pub 2024. PMID: 39585341.
13. Serrano AG, Rocha P, Freitas Lima C, Stewart A, Zhang B, Diao L, Fujimoto J, Cardnell RJ, Lu W, Khan K, Sable B, Ellison AR, Wistuba II, Concannon KF, Halperin DM, Bogdan C, Sircar K, Zhang M, Cargill K, Wang Q, Aparicio A, Lazar A, Hernandez S, Estrella J, Ramalingam P, El-Naggar A, Kalhor N, Gay CM, Byers LA, Solis Soto LM. Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms. NPJ Precis Oncol 8(1):268, 2024. e-Pub 2024. PMID: 39558076.
14. Karim NA, Miao J, Reckamp KL, Gay CM, Byers LA, Zhao YQ, Redman MW, Carrizosa DR, Wang WL, Petty WJ, Mehta K, Faller BA, Agamah ES, Kasbari SS, Malisetti RK, Kumar A, Schallenkamp J, Alluri KC, Gray JE, Kelly K. Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929. J Thorac Oncol 20(3):383-394, 2024. e-Pub 2024. PMID: 39505259.
15. Murray CE, Kornepati AVR, Ontiveros C, Liao Y, de la Pena Avalos B, Rogers CM, Liu Z, Deng Y, Bai H, Kari S, Padron AS, Boyd JT, Reyes R, Clark CA, Svatek RS, Li R, Hu Y, Wang M, Conejo-Garcia JR, Byers LA, Ramkumar K, Sood AK, Lee JM, Burd CE, Vadlamudi RK, Gupta HB, Zhao W, Dray E, Sung P, Curiel TJ. Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors. Mol Cancer 23(1):242, 2024. e-Pub 2024. PMID: 39478560.
16. Zhou N, Leung CH, William Jr WN, Pataer A, Godoy MCB, Carter BW, Fossella FV, Tsao AS, Blumenschein Jr GR, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Tran HT, Wu J, Solis LM, Kadarah H, Swisher SG, Vaporciyan AA, Gibbons DL, Lin HY, Lee JJ, Heymach JV, Sepesi B, Cascone T. Impact of Select Actionable Genomic Alterations on Efficacy of Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. J Immunother Cancer, 2024. e-Pub 2024. PMID: 39448200.
17. Stewart C, Diao L, Xi Y, Wang R, Ramkumar K, Serrano AG, Tanimoto A, Rodriguez B, Morris BB, Shen L, Zhang B, Yang Y, Hamad SH, Cardnell RJ, Jr AD, Sahu M, Novegil VY, Weissman BE, Frumovitz M, Kalhor N, Soto LS, Rocha PD, Vokes N, Gibbons DL, Wang J, Heymach JV, Glisson B, Byers LA, Gay CM. YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities. Clin Cancer Res 30(20):4743-4754, 2024. e-Pub 2024. PMID: 39150543.
18. Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, M Lau SC, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee J, Bivona TG, Camidge D, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA-4 blockade abrogates KEAP1/STK11-related PD-(L)1-inhibitor resistance. Nature 635(8038):462-471, 2024. e-Pub 2024. PMID: 39385035.
19. Xie, M, Vuko, M, Rodriguez Canales, J, Zimmermann, J, Schick, M, O’Brien, C, Paz-Ares, L, Goldman, JW, Garassino, MC, Gay, CM, Heymach, JV, Jiang, H, Barrett, JC, Stewart, RA, Lai, Z, Byers, LA, Rudin, CM, Shrestha, Y. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer. Molecular cancer 23(1), 2024. e-Pub 2024. PMID: 38811992.
20. Aminu M, Zhu B, Vokes N, Chen H, Hong L, Li J, Fujimoto J, Yang Y, Wang T, Wang B, Poteete A, Nilsson MB, Le X, Tina C, Jaffray D, Navin N, Byers LA, Gibbons D, Heymach J, Chen K, Cheng C, Zhang J, Wu J. CoCo-ST: Comparing and Contrasting Spatial Transcriptomics data sets using graph contrastive learning. Res Sq, 2024. e-Pub 2024. PMID: 38826463.
21. Aminu M, Hong L, Vokes N, Schmidt ST, Saad M, Zhu B, Le X, Tina C, Sheshadri A, Wang B, Jaffray D, Futreal A, Lee JJ, Byers LA, Gibbons D, Heymach J, Chen K, Cheng C, Zhang J, Wu J. Joint multi-omics discriminant analysis with consistent representation learning using PANDA. Res Sq, 2024. e-Pub 2024. PMID: 38798352.
22. Park, S, Hong, TH, Hwang, S, Heeke, S, Gay, CM, Kim, J, Jung, HA, Sun, JM, Ahn, JS, Ahn, MJ, Cho, JH, Choi, YS, Kim, J, Shim, YM, Kim, HK, Byers, LA, Heymach, JV, Choi, YL, Lee, SH, Park, K. Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer. EBioMedicine 102, 2024. e-Pub 2024. PMID: 38492534.
23. Wang K, Du R, Myall NJ, Lewis WE, Uy N, Hong L, Skoulidis F, Byers LA, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao MV, Gibbons DL, Park K, Rinsurongkawong W, Lee JJ, Gandara D, Behl D, Shu CA, Riess JW, Baik C, Wakelee HA, Vaporciyan AA, Heymach JV, Zhang J, Le X. BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC). J Thorac Oncol 19(3):S1556-0864(23)02376-6, 2024. e-Pub 2024. PMID: 38012986.
24. Nabet, BY, Hamidi, H, Lee, MC, Banchereau, R, Morris, S, Adler, L, Gayevskiy, V, Elhossiny, AM, Srivastava, MK, Patil, NS, Smith, KA, Jesudason, R, Chan, C, Chang, PS, Fernandez, M, Rost, S, McGinnis, LM, Koeppen, H, Gay, CM, Minna, J, Heymach, JV, Chan, JM, Rudin, CM, Byers, LA, Liu, SV, Reck, M, Shames, DS. Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer cell 42(3):429-443.e4, 2024. e-Pub 2024. PMID: 38366589.
25. Heeke S, Gay CM, Estecio MR, Tran H, Morris BB, Zhang B, Tang X, Raso MG, Rocha P, Lai S, Arriola E, Hofman P, Hofman V, Kopparapu P, Lovly CM, Concannon K, De Sousa LG, Lewis WE, Kondo K, Hu X, Tanimoto A, Vokes NI, Nilsson MB, Stewart A, Jansen M, Horváth I, Gaga M, Panagoulias V, Raviv Y, Frumkin D, Wasserstrom A, Shuali A, Schnabel CA, Xi Y, Diao L, Wang Q, Zhang J, Loo PV, Wang J, Wistuba II, Byers LA. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell 42(2):225-237, 2024. e-Pub 2024. PMID: 38278149.
26. Zhang, B, Lewis, WE, Stewart, C, Morris, BB, Solis Soto, LM, Serrano, A, Xi, Y, Wang, Q, Lopez, ER, Concannon, K, Heeke, S, Tang, X, Raso, G, Cardnell, R, Vokes, N, Blumenschein, GR, Elamin, YY, Fosella, F, Tsao, A, Skoulidis, F, Hume, CB, Sasak, K, Lewis, J, Rinsurongkawong, W, Rinsurongkawong, V, Lee, JJ, Tran, HT, Zhang, J, Gibbons, DL, Vaporciyan, AA, Wang, J, Park, K, Heymach, JV, Byers, LA, Gay, CM, Le, X. Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets. JTO Clinical and Research Reports 5(2), 2024. e-Pub 2024. PMID: 38357092.
27. Zhang B, Morris BB, Solis LM, Serrano A, Xi Y, Wang Q, Lopez ER, Concannon K, Heeke S, Tang X, Raso G, Cardnell RJ, Vokes N, Blumenschein G, Elamin Y, Fosella F, Tsao A, Skoulidis F, Hume CB, Sasak K, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Tran H, Zhang J, Gibbons D, Vaporciyan A, Wang J, Park K, Heymach JV, Byers LA, Gay CM, Le X. Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets. JTO Clin Res Rep 5(2):100623, 2023. e-Pub 2023. PMID: 38357092.
28. Altan M, Li Q, Wang Q, Vokes NI, Sheshadri A, Gao J, Zhu C, Tran HT, Gandhi S, Antonoff MB, Swisher S, Wang J, Byers LA, Abdel-Wahab N, Franco-Vega MC, Wang Y, Lee J, Zhang J, Heymach JV. Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events. Front Immunol 14, 2023. e-Pub 2023. PMID: 38152395.
29. Liu SV, Mok TSK, Nabet BY, Mansfield AS, de Boer RA, Losonczy G, Sugawara S, Dziadziuszko R, Krzakowski M, Smolin A, Hochmair MJ, Garassino MC, Gay CM, Heymach JV, Byers LA, Lam S, Cardona A, Morris S, Adler L, Reck M. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide. Lung Cancer 186, 2023. e-Pub 2023. PMID: 37931445.
30. Zhou D, Byers LA, Sable B, Smit MD, Sadraei NH, Dutta S, Upreti VV. Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-like ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC). J Clin Pharmacol 64(3):362-370, 2023. e-Pub 2023. PMID: 37694295.
31. Megyesfalvi Z, Heeke S, Drapkin BJ, Solta A, Kovacs I, Boettiger K, Horvath L, Ernhofer B, Fillinger J, Renyi-Vamos F, Aigner C, Schelch K, Lang C, Marko-Varga G, Gay CM, Byers LA, Morris BB, Heymach JV, Van Loo P, Hirsch FR, Dome B. Unfolding the secrets of small cell lung cancer progression: Novel approaches and insights through rapid autopsies. Cancer Cell 41(9):1535-1540, 2023. e-Pub 2023. PMID: 37699331.
32. Ramkumar K, Tanimoto A, Della Corte CM, Stewart CA, Wang Q, Shen L, Cardnell RJ, Wang J, Polanska UM, Andersen C, Saeh J, Pease JE, Travers J, Fabbri G, Gay CM, Urosevic J, Byers LA. Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer. Clin Cancer Res 29(16):3237-3249, 2023. e-Pub 2023. PMID: 37289191.
33. Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
34. Nelson BE, Roszik J, Janku F, Hong DS, Kato S, Naing A, Piha-Paul S, Fu S, Tsimberidou A, Cabanillas M, Busaidy NL, Javle M, Byers LA, Heymach JV, Meric-Bernstam F, Subbiah V. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol 7(1):19, 2023. e-Pub 2023. PMID: 36801912.
35. Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SH. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer 174:112-117, 2022. e-Pub 2022. PMID: 36371941.
36. Della Corte CM, Ciaramella V, Ramkumar K, Vicidomini G, Fiorelli A, Nardone V, Cappabianca S, Cozzolino I, Zito Marino F, Di Guida G, Wang Q, Cardnell R, Gay CM, Ciardiello D, Martinelli E, Troiani T, Martini G, Napolitano S, Wang J, Byers LA, Ciardiello F, Morgillo F. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC. J Transl Med 20(1):541, 2022. e-Pub 2022. PMID: 36419183.
37. Zhang B, Stewart CA, Wang Q, Cardnell RJ, Rocha P, Fujimoto J, Solis Soto LM, Wang R, Novegil V, Ansell P, He L, Fernandez L, Jendrisak A, Gilbertson C, Schonhoft JD, Byun J, Jones J, Anderson AKL, Aparicio A, Tran H, Negrao MV, Zhang J, Wang WL, Wistuba II, Wang J, Wenstrup R, Byers LA, Gay CM. Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. Br J Cancer 127(3):569-576, 2022. e-Pub 2022. PMID: 35440668.
38. Rimner A, Lai WV, Califano R, Jabbour SK, Rudin CM, Faivre-Finn C, Cho BC, Kato T, Yu J, Chafin W, Yu L, Zhao B, Byers L. Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer. Clin Lung Cancer 23(5):e325-e329, 2022. e-Pub 2022. PMID: 35613997.
39. Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell 40(7):754-767.e6, 2022. e-Pub 2022. PMID: 35820397.
40. Schmidt ST, Akhave N, Knightly RE, Reuben A, Vokes N, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget MA, McGrail DJ, Weissferdt A, Lin SY, Lee Y, Suzuki E, Kovacs JJ, Behrens C, Wistuba II, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Cascone T, Zhang J, Bristow CA, Heffernan TP, Negrao MV, Gibbons DL, Team I. Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set. JCO Clin Cancer Inform 6:e2200040, 2022. e-Pub 2022. PMID: 35944232.
41. Della Corte CM, Fasano M, Ciaramella V, Cimmino F, Cardnell R, Gay CM, Ramkumar K, Diao L, Di Liello R, Viscardi G, Famiglietti V, Ciardiello D, Martini G, Napolitano S, Tuccillo C, Troiani T, Martinelli E, Wang J, Byers L, Morgillo F, Ciardiello F. Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial. J Exp Clin Cancer Res 41(1):109, 2022. e-Pub 2022. PMID: 35346313.
42. Federico L, McGrail DJ, Bentebibel SE, Haymaker C, Ravelli A, Forget MA, Karpinets T, Jiang P, Reuben A, Negrao MV, Li J, Khairullah R, Zhang J, Weissferdt A, Vaporciyan AA, Antonoff MB, Walsh G, Lin SY, Futreal A, Wistuba I, Roth J, Byers LA, Gaudreau PO, Uraoka N, Cruz AF, Dejima H, Lazcano RN, Solis LM, Parra ER, Lee JJ, Swisher S, Cascone T, Heymach JV, Zhang J, Sepesi B, Gibbons DL, Bernatchez C. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. Ann Oncol 33(1):42-56, 2022. e-Pub 2022. PMID: 34653632.
43. Byers LA, Navarro A, Schaefer E, Johnson M, Özgüroglu M, Han JY, Bondarenko I, Cicin I, Dragnev KH, Abel A, Wang X, McNeely S, Hynes S, Lin AB, Forster M. A Phase II Trial of Prexasertib (LY2606368) in Patients with Extensive-Stage Small-Cell Lung Cancer. Clin Lung Cancer 22(6):531-540, 2021. e-Pub 2021. PMID: 34034991.
44. Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Zhang B, Della Corte CM, Fan Y, Kundu K, Gao B, Avila K, Pickering CR, Johnson FM, Zhang J, Kadara H, Minna JD, Gibbons DL, Wang J, Heymach JV, Byers LA. Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. J Thorac Oncol S1556-0864(21):1821-1839, 2021. e-Pub 2021. PMID: 34274504.
45. Ramalingam SS, Novello S, Guclu SZ, Bentsion D, Zvirbule Z, Szilasi M, Bernabe R, Syrigos K, Byers LA, Clingan P, Bar J, Vokes EE, Govindan R, Dunbar M, Ansell P, He L, Huang X, Sehgal V, Glasgow J, Bach BA, Mazieres J. Veliparib in Combination with Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. J Clin Oncol 39(32):3633-3644, 2021. e-Pub 2021. PMID: 34436928.
46. Chen M, Chen R, Jin Y, Li J, Hu X, Zhang J, Fujimoto J, Hubert SM, Gay CM, Zhu B, Tian Y, McGranahan N, Lee WC, George J, Hu X, Chen Y, Wu M, Behrens C, Chow CW, Pham HHN, Fukuoka J, Wu J, Parra ER, Little LD, Gumbs C, Song X, Wu CJ, Diao L, Wang Q, Cardnell R, Zhang J, Wang J, Le X, Gibbons DL, Heymach JV, Jack Lee J, William WN, Cheng C, Glisson B, Wistuba I, Andrew Futreal P, Thomas RK, Reuben A, Byers LA, Zhang J. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nat Commun 12(1):6655, 2021. e-Pub 2021. PMID: 34789716.
47. Kundu K, Cardnell RJ, Zhang B, Shen L, Stewart CA, Ramkumar K, Cargill KR, Wang J, Gay CM, Byers LA. SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer. Transl Lung Cancer Res 10(11):4095-4105, 2021. e-Pub 2021. PMID: 35004241.
48. Sinjab A, Han G, Treekitkarnmongkol W, Hara K, Brennan PM, Dang M, Hao D, Wang R, Dai E, Dejima H, Zhang J, Bogatenkova E, Sanchez-Espiridion B, Chang K, Little DR, Bazzi S, Tran LM, Krysan K, Behrens C, Duose DY, Parra ER, Raso MG, Solis LM, Fukuoka J, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Rosen D, Heymach JV, Scheet P, Dubinett SM, Fujimoto J, Wistuba II, Stevenson CS, Spira A, Wang L, Kadara H. Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-cell Sequencing. Cancer Discov 11(10):2506-2523, 2021. e-Pub 2021. PMID: 33972311.
49. Cargill KR, Stewart CA, Park EM, Ramkumar K, Gay CM, Cardnell RJ, Wang Q, Diao L, Shen L, Fan YH, Chan WK, Lorenzi PL, Oliver TG, Wang J, Byers LA. Targeting MYC-enhanced Glycolysis for the Treatment of Small Cell Lung Cancer. Cancer Metab 9(1):33, 2021. e-Pub 2021. PMID: 34556188.
50. Tran HT, Lam VK, Elamin YY, Hong L, Colen R, Elshafeey NA, Hassan ISA, Altan M, Blumenschein GR, Rinsurongkawong W, Rivera MJ, Vasquez ME, Carter BW, Byers LA, Tsao AS, Gibbons DL, Fossella F, Glisson BS, Zhang J, Heymach JV. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precis Oncol 5:1241-1249, 2021. e-Pub 2021. PMID: 34377884.
51. Argiris A, Miao J, Cristea MC, Chen AM, Sands JM, Decker RH, Gettinger SN, Daly ME, Faller BA, Albain KS, Yanagihara RH, Garland LL, Byers LA, Wang D, Koczywas M, Redman MW, Kelly K, Gandara DR. A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy with or without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811). Clin Lung Cancer 22(4):313-323, 2021. e-Pub 2021. PMID: 33745865.
52. Byers LA, Bentsion D, Gans S, Penkov K, Son C, Sibille A, Owonikoko TK, Groen HJM, Gay CM, Fujimoto J, de Groot P, Dunbar M, Kang K, He L, Sehgal V, Glasgow J, Bach BA, Ellis PM. Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study. Clin Cancer Res 27(14):3884-3895, 2021. e-Pub 2021. PMID: 33947690.
53. Subbiah V, Shen T, Tetzlaff M, Weissferdt A, Byers LA, Cascone T, Behrang A, Meric-Bernstam F, Mooers BHM, Rothenberg SM, Ebata K, Wu J. Patient-driven Discovery and Post-clinical Validation of NTRK3 Fusion as an Acquired Resistance Mechanism to Selpercatinib in RET Fusion-positive Lung Cancer. Ann Oncol 32(6):817-819, 2021. e-Pub 2021. PMID: 33617938.
54. Owonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Al Baghdadi T, Lara P, Miao J, Kelly K, Ramalingam SS, Herbst RS, Papadimitrakopoulou V, Gandara DR. Phase 2 Study of Talazoparib in Patients with Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. Clin Lung Cancer 22(3):187-194.e1, 2021. e-Pub 2021. PMID: 33583720.
55. Peng DH, Rodriguez BL, Diao L, Gaudreau PO, Padhye A, Konen JM, Ochieng JK, Class CA, Fradette JJ, Gibson L, Chen L, Wang J, Byers LA, Gibbons DL. Th17 Cells Contribute to Combination MEK Inhibitor and Anti-PD-L1 Therapy Resistance in KRAS/p53 Mutant Lung Cancers. Nat Commun 12(1):2606, 2021. e-Pub 2021. PMID: 33972557.
56. Le X, Negrao MV, Reuben A, Federico L, Diao L, McGrail D, Nilsson M, Robichaux J, Munoz IG, Patel S, Elamin Y, Fan YH, Lee WC, Parra E, Solis Soto LM, Chen R, Li J, Karpinets T, Khairullah R, Kadara H, Behrens C, Sepesi B, Wang R, Zhu M, Wang L, Vaporciyan A, Roth J, Swisher S, Haymaker C, Zhang J, Wang J, Wong KK, Byers LA, Bernatchez C, Zhang J, Wistuba II, Gibbons DL, Akbay EA, Heymach JV. Characterization of the Immune Landscape of EGFR-mutant NSCLC Identifies CD73/adenosine Pathway as a Potential Therapeutic Target. J Thorac Oncol 16(4):583-600, 2021. e-Pub 2021. PMID: 33388477.
57. Iommelli F, De Rosa V, Terlizzi C, Fonti R, Camerlingo R, Stoppelli MP, Stewart CA, Byers LA, Piwnica-Worms D, Del Vecchio S. A Reversible Shift of Driver Dependence from EGFR to Notch1 in Non-Small Cell Lung Cancer as a Cause of Resistance to Tyrosine Kinase Inhibitors. Cancers (Basel) 13(9), 2021. e-Pub 2021. PMID: 33922104.
58. Ramkumar K, Stewart CA, Cargill KR, Della Corte CM, Wang Q, Shen L, Diao L, Cardnell RJ, Peng DH, Rodriguez BL, Fan YH, Heymach JV, Wang J, Gay CM, Gibbons DL, Byers LA. AXL Inhibition Induces DNA Damage and Replication Stress in Non-small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. Mol Cancer Res 19(3):485-497, 2021. e-Pub 2021. PMID: 33172976.
59. Konen JM, Rodriguez BL, Padhye A, Ochieng JK, Gibson L, Diao L, Fowlkes NW, Fradette JJ, Peng DH, Cardnell RJ, Kovacs JJ, Wang J, Byers LA, Gibbons DL. Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-mesenchymal Transition in NSCLC. Cancer Res 81(5):1398-1412, 2021. e-Pub 2021. PMID: 33402388.
60. Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Wang Q, Fabbri G, Cargill KR, Vokes NI, Ramkumar K, Zhang B, Della Corte CM, Robson P, Swisher SG, Roth JA, Glisson BS, Shames DS, Wistuba II, Wang J, Quaranta V, Minna J, Heymach JV, Byers LA. Patterns of Transcription Factor Programs and Immune Pathway Activation Define Four Major Subtypes of SCLC with Distinct Therapeutic Vulnerabilities. Cancer Cell 39(3):346-360.e7, 2021. e-Pub 2021. PMID: 33482121.
61. Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Operable Non-small Cell Lung Cancer: The Phase 2 Randomized NEOSTAR Trial. Nat Med 27(3):504-514, 2021. e-Pub 2021. PMID: 33603241.
62. Han G, Sinjab A, Hara K, Treekitkarnmongkol W, Brennan P, Chang K, Bogatenkova E, Sanchez-Espiridion B, Behrens C, Solis LM, Gao B, Girard L, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Scheet P, Fujimoto J, Shay J, Heymach JV, Minna JD, Dubinett S, Wistuba II, Stevenson CS, Spira AE, Wang L, Kadara H. Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers (Basel) 13(6):1-13, 2021. e-Pub 2021. PMID: 33809063.
63. Huang F, Huffman KE, Wang Z, Wang X, Li K, Cai F, Yang C, Cai L, Shih TS, Zacharias LG, Chung A, Yang Q, Chalishazar MD, Ireland AS, Stewart CA, Cargill K, Girard L, Liu Y, Ni M, Xu J, Wu X, Zhu H, Drapkin B, Byers LA, Oliver TG, Gazdar AF, Minna JD, DeBerardinis RJ. Guanosine Triphosphate Links MYC-dependent Metabolic and Ribosome Programs in Small Cell Lung Cancer. J Clin Invest 131(1), 2021. e-Pub 2021. PMID: 33079728.
64. Welsh JW, Heymach JV, Guo C, Menon H, Klein K, Cushman TR, Verma V, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Comeaux N, Patel RR, Chen D, Ozgen T, Nguyen QN, Chang JY, Altan M, Zhang J, Papadimitrakopoulou VA, Simon GR, Byers LA, Glisson B. Phase I/II Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage Small Cell Lung Cancer. J Thorac Oncol 15(12):1919-1927, 2020. e-Pub 2020. PMID: 32916308.
65. Cherng HJ, Jain N, Thakral B, Muzzafar T, Miranda RN, Tan D, Rashid A, Kalhor N, Hahn AW, Byers LA, Parseghian CM, Ferrajoli A, Pemmaraju N. Metastatic Lung Adenocarcinoma Mimicking Richter Transformation in a Patient with Chronic Lymphocytic Leukemia. Leuk Res 98:106445, 2020. e-Pub 2020. PMID: 32937250.
66. Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol 15(9):1449-1459, 2020. e-Pub 2020. PMID: 32389639.
67. Carroll MR, Ramalingam P, Salvo G, Fujimoto J, Solis Soto LM, Phoolcharoen N, Hillman RT, Cardnell R, Byers L, Frumovitz M. Evaluation of PARP and PDL-1 as Potential Therapeutic Targets for Women with High-grade Neuroendocrine Carcinomas of the Cervix. Int J Gynecol Cancer 30(9):1303-1307, 2020. e-Pub 2020. PMID: 32727929.
68. Peng DH, Rodriguez BL, Diao L, Chen L, Wang J, Byers LA, Wei Y, Chapman HA, Yamauchi M, Behrens C, Raso G, Soto LMS, Cuentes ERP, Wistuba II, Kurie JM, Gibbons DL. Collagen Promotes Anti-PD-1/PD-L1 Resistance in Cancer Through LAIR1-dependent CD8+ T Cell Exhaustion. Nat Commun 11(1):4520, 2020. e-Pub 2020. PMID: 32908154.
69. Della Corte CM, Sen T, Gay CM, Ramkumar K, Diao L, Cardnell RJ, Rodriguez BL, Stewart CA, Papadimitrakopoulou VA, Gibson L, Fradette JJ, Wang Q, Fan Y, Peng DH, Negrao MV, Wistuba II, Fujimoto J, Solis Soto LM, Behrens C, Skoulidis F, Heymach JV, Wang J, Gibbons DL, Byers LA. STING Pathway Expression Identifies Non-small Cell Lung Cancers with an Immune-responsive Phenotype. J Thorac Oncol 15(5):777-791, 2020. e-Pub 2020. PMID: 32068166.
70. Pezzi TA, Schwartz DL, Pisters KMW, Mohamed ASR, Welsh JW, Chang JY, Liao Z, Gandhi SJ, Byers LA, Minsky BD, Fuller CD, Chun SG. Association of Medicaid Insurance with Survival Among Patients with Small Cell Lung Cancer. JAMA Netw Open 3(4):e203277, 2020. e-Pub 2020. PMID: 32320035.
71. Stewart CA, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, Bolisetty M, Hartsfield PM, Balasubramaniyan V, Chalishazar MD, Moran C, Kalhor N, Stewart J, Tran H, Swisher SG, Roth JA, Zhang J, de Groot J, Glisson B, Oliver TG, Heymach JV, Wistuba I, Robson P, Wang J, Byers LA. Single-cell Analyses Reveal Increased Intratumoral Heterogeneity after the Onset of Therapy Resistance in Small-cell Lung Cancer. Nat Cancer 1(4):423-436, 2020. e-Pub 2020. PMID: 33521652.
72. Cristea S, Coles GL, Hornburg D, Gershkovitz M, Arand J, Cao S, Sen T, Williamson SC, Kim JW, Drainas AP, He A, Cam LL, Byers LA, Snyder MP, Contrepois K, Sage J. The MEK5-ERK5 Kinase Axis Controls Lipid Metabolism in Small Cell Lung Cancer. Cancer Res 80(6):1293-1303, 2020. e-Pub 2020. PMID: 31969375.
73. Welsh JW, Heymach JV, Chen D, Verma V, Cushman TR, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Menon H, Nguyen QN, Chang JY, Altan M, Papadimitrakopoulou VA, Simon GR, Raju U, Byers L, Glisson B. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. J Thorac Oncol 15(2):266-273, 2020. e-Pub 2020. PMID: 31605794.
74. Owonikoko TK, Niu H, Nackaerts K, Csoszi T, Ostoros G, Mark Z, Baik C, Joy AA, Chouaid C, Jaime JC, Kolek V, Majem M, Roubec J, Santos ES, Chiang AC, Speranza G, Belani CP, Chiappori A, Patel MR, Czebe K, Byers L, Bahamon B, Li C, Sheldon-Waniga E, Kong EF, Williams M, Badola S, Shin H, Bedford L, Ecsedy JA, Bryant M, Jones S, Simmons J, Leonard EJ, Ullmann CD, Spigel DR, investigators CS. Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses. J Thorac Oncol 15(2):274-287, 2020. e-Pub 2020. PMID: 31655296.
75. Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab with Chemoradiation in Unresectable Non-small Cell Lung Cancer. J Thorac Oncol 15(2):248-257, 2020. e-Pub 2020. PMID: 31778797.
76. Hillman RT, Cardnell R, Fujimoto J, Lee WC, Zhang J, Byers LA, Ramalingam P, Leitao M, Swisher E, Futreal PA, Frumovitz M. Comparative Genomics of High-Grade Neuroendocrine Carcinoma of the Cervix. PLoS One 15(6):e0234505, 2020. e-Pub 2020. PMID: 32544169.
77. Sen T, Della Corte CM, Milutinovic S, Cardnell RJ, Diao L, Ramkumar K, Gay CM, Stewart CA, Fan Y, Shen L, Hansen RJ, Strouse B, Hedrick MP, Hassig CA, Heymach JV, Wang J, Byers LA. Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC. J Thorac Oncol 14(12):2152-2163, 2019. e-Pub 2019. PMID: 31470128.
78. Chen PH, Cai L, Huffman K, Yang C, Kim J, Faubert B, Boroughs L, Ko B, Sudderth J, McMillan EA, Girard L, Chen D, Peyton M, Shields MD, Yao B, Shames DS, Kim HS, Timmons B, Sekine I, Britt R, Weber S, Byers LA, Heymach JV, Chen J, White MA, Minna JD, Xiao G, DeBerardinis RJ. Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells. Mol Cell 76(5):838-851.e5, 2019. e-Pub 2019. PMID: 31564558.
79. Massarelli E, Lam VK, Parra ER, Rodriguez-Canales J, Behrens C, Diao L, Wang J, Blando J, Byers LA, Yanamandra N, Brett S, Morley P, Sharma P, Allison J, Wistuba II, Heymach JV. High OX-40 Expression in the Tumor Immune Infiltrate is a Favorable Prognostic Factor of Overall Survival in Non-small Cell Lung Cancer. J Immunother Cancer 7(1):351, 2019. e-Pub 2019. PMID: 31843013.
80. Dammert MA, Brägelmann J, Olsen RR, Böhm S, Monhasery N, Whitney CP, Chalishazar MD, Tumbrink HL, Guthrie MR, Klein S, Ireland AS, Ryan J, Schmitt A, Marx A, Ozretic L, Castiglione R, Lorenz C, Jachimowicz RD, Wolf E, Thomas RK, Poirier JT, Büttner R, Sen T, Byers LA, Reinhardt HC, Letai A, Oliver TG, Sos ML. MYC Paralog-dependent Apoptotic Priming Orchestrates a Spectrum of Vulnerabilities in Small Cell Lung Cancer. Nat Commun 10(1):3485, 2019. e-Pub 2019. PMID: 31375684.
81. Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, Fan Y, Yang Y, Wang J, Glisson BS, Wistuba II, Sage J, Heymach JV, Gibbons DL, Byers LA. Targeting DNA Damage Response Promotes Anti-tumor Immunity through STING-mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discov 9(5):646-661, 2019. e-Pub 2019. PMID: 30777870.
82. Kim J, Hu Z, Cai L, Li K, Choi E, Faubert B, Bezwada D, Rodriguez-Canales J, Villalobos P, Lin YF, Ni M, Huffman KE, Girard L, Byers LA, Unsal-Kacmaz K, Peña CG, Heymach JV, Wauters E, Vansteenkiste J, Castrillon DH, Chen BPC, Wistuba I, Lambrechts D, Xu J, Minna JD, DeBerardinis RJ. CPS1 Maintains Pyrimidine Pools and DNA Synthesis in KRAS/LKB1-mutant Lung Cancer Cells (Author Correction). Nature 569(7756):E4, 2019. e-Pub 2019. PMID: 31043737.
83. Peng DH, Kundu ST, Fradette JJ, Diao L, Tong P, Byers LA, Wang J, Canales JR, Villalobos PA, Mino B, Yang Y, Minelli R, Peoples MD, Bristow CA, Heffernan TP, Carugo A, Wistuba II, Gibbons DL. ZEB1 Suppression Sensitizes KRAS Mutant Cancers to MEK Inhibition by an IL17RD-dependent Mechanism. Sci Transl Med 11(483), 2019. e-Pub 2019. PMID: 30867319.
84. Gay CM, Tong P, Cardnell RJ, Sen T, Su X, Ma J, Bara RO, Johnson FM, Wakefield C, Heymach JV, Wang J, Byers LA. Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers. Clin Cancer Res 25(1):346-357, 2019. e-Pub 2019. PMID: 30257981.
85. Atrafi F, Groen HJM, Byers LA, Garralda E, Lolkema MP, Sangha RS, Viteri S, Chae YK, Camidge DR, Gabrail NY, Hu B, Tian T, Nuthalapati S, Hoening E, He L, Komarnitsky P, Calles A. A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors. Clin Cancer Res 25(2):496-505, 2019. e-Pub 2019. PMID: 30327308.
86. Della Corte CM, Gay CM, Byers LA, Morgillo F. ILK and SHP2 Expression Identify a Poor Prognostic Cohort of EGFR-mutant Lung Cancer. EBioMedicine 39:5-6, 2019. e-Pub 2019. PMID: 30553753.
87. Nong J, Gong Y, Guan Y, Yi X, Yi Y, Chang L, Yang L, Lv J, Guo Z, Jia H, Chu Y, Liu T, Chen M, Byers LA, Roarty E, Lam VK, Papadimitrakopoulou VA, Wistuba I, Heymach JV, Glisson B, Liao Z, Lee JJ, Futreal PA, Zhang S, Xia X, Zhang J, Wang J. Author Correction: Circulating Tumor DNA Analysis Depicts Subclonal Architecture and Genomic Evolution of Small Cell Lung Cancer. Nat Commun 10(1):552, 2019. e-Pub 2019. PMID: 30696827.
88. Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J, Network TR, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov 8(12):1548-1565, 2018. e-Pub 2018. PMID: 30322867.
89. Cascone, T, William Jr, WN, Weissferdt, A, Leung, CH, Federico, L, Haymaker, CL, Bernatchez, C, Fossella, FV, Mott, FE, Papadimitrakopoulou, VA, Byers, LA, Lam, VK, Godoy, M, Carter, B, Lee, JJ, Vaporciyan, AA, Gibbons, DL, Swisher, SG, Heymach, JV, Sepesi, B. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC). Annals of oncology : official journal of the European Society for Medical Oncology 29:viii738, 2018. e-Pub 2018. PMID: 32138023.
90. Della Corte, CM, Ramkumar, K, Sen, T, Tong, P, Gibbons, DL, Heymach, JV, Wang, J, Fan, YH, Cardnell, R, Byers, LA. DNA damaging agents and immunotherapy in NSCLC. 43rd ESMO Congress (ESMO 2018) 29:viii45, 2018. PMID: 32137147.
91. Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette JJ, Peng DH, Ungewiss C, Roybal J, Tong P, Oba J, Skoulidis F, Peng W, Carter BW, Gay CM, Fan Y, Class CA, Zhu J, Rodriguez-Canales J, Kawakami M, Byers LA, Woodman SE, Papadimitrakopoulou VA, Dmitrovsky E, Wang J, Ullrich SE, Wistuba II, Heymach JV, Qin FX, Gibbons DL. CD38-mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov 8(9):1156-1175, 2018. e-Pub 2018. PMID: 30012853.
92. Ferrarotto R, Cardnell R, Su S, Diao L, Eterovic AK, Prieto V, Morrisson WH, Wang J, Kies MS, Glisson BS, Byers LA, Bell D. Poly ADP-ribose Polymerase-1 as a Potential Therapeutic Target in Merkel Cell Carcinoma. Head Neck 40(8):1676-1684, 2018. e-Pub 2018. PMID: 29570891.
93. Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, Long L, Diao L, Wang J, Bensman Y, Hurtado B, de Groot P, Sulman EP, Wistuba II, Chen A, Fleisher M, Heymach JV, Kris MG, Rudin CM, Byers LA. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination with Either Veliparib or Placebo in Patients with Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol 36(23):JCO2018777672, 2018. e-Pub 2018. PMID: 29906251.
94. Nong J, Gong Y, Guan Y, Yi X, Yi Y, Chang L, Yang L, Lv J, Guo Z, Jia H, Chu Y, Liu T, Chen M, Byers L, Roarty E, Lam VK, Papadimitrakopoulou VA, Wistuba I, Heymach JV, Glisson B, Liao Z, Lee JJ, Futreal PA, Zhang S, Xia X, Zhang J, Wang J. Circulating Tumor DNA Analysis Depicts Subclonal Architecture and Genomic Evolution of Small Cell Lung Cancer. Nat Commun 9(1):3114, 2018. e-Pub 2018. PMID: 30082701.
95. Tanaka I, Sato M, Kato T, Goto D, Kakumu T, Miyazawa A, Yogo N, Hase T, Morise M, Sekido Y, Girard L, Minna JD, Byers LA, Heymach JV, Coombes KR, Kondo M, Hasegawa Y. eIF2β, a Subunit of Translation-Initiation Factor EIF2, Is a Potential Therapeutic Target for Non-Small Cell Lung Cancer. Cancer Sci 109(6):1843-1852, 2018. e-Pub 2018. PMID: 29624814.
96. Sen, S, Kato, SM, Agarwal, R, Piha-Paul, SA, Hess, KR, Karp, DD, Janku, F, Fu, S, Naing, A, Pant, S, Falchook, GS, Tang, C, Wu, X, Ye, Y, Tsimberidou, AM, Subbiah, V, Kurzrock, R, Byers, LA, Westin, SN, Lim, J, Bean, S, Bass, A, Nguyen, LH, Meric-Bernstam, F, Hong, DS. Phase i study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. British journal of cancer 118(11):1419-1424, 2018. e-Pub 2018. PMID: 29695765.
97. Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK, Research Network CGA, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep 23(1):194-212.e6, 2018. e-Pub 2018. PMID: 29617660.
98. Suzuki R, Lin SH, Wei X, Allen PK, Welsh JW, Byers LA, Komaki R. Prognostic Significance of Pretreatment Total Lymphocyte Count and Neutrophil-to-lymphocyte Ratio in Extensive-stage Small-cell Lung Cancer. Radiother Oncol 126(3):499-505, 2018. e-Pub 2018. PMID: 29398150.
99. Gomez DR, Byers LA, Nilsson M, Diao L, Wang J, Li L, Tong P, Hofstad M, Saigal B, Wistuba I, Kalhor N, Swisher S, Fan Y, Hong WK, Suraokar M, Behrens C, Moran C, Heymach JV. Integrative Proteomic and Transcriptomic Analysis Provides Evidence for TrkB (NTRK2) as a Therapeutic Target in Combination with Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer. Oncotarget 9(18):14268-14284, 2018. e-Pub 2018. PMID: 29581842.
100. Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative Study of Lung and Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A SEER Database Analysis of 162,983 Cases. Cancer 124(4):807-815, 2018. e-Pub 2018. PMID: 29211313.
101. Gadhikar MA, Zhang J, Shen L, Rao X, Wang J, Zhao M, Kalu NN, Johnson FM, Byers LA, Heymach J, Hittelman WN, Udayakumar D, Pandita RK, Pandita TK, Pickering CR, Redwood AB, Piwnica-Worms H, Schlacher K, Frederick MJ, Myers JN. CDKN2A/p16Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. Cancer Res 78(3):781-797, 2018. e-Pub 2018. PMID: 29229598.
102. Research Network CGA. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell 171(4):950-965.e28, 2017. e-Pub 2017. PMID: 29100075.
103. Sen T, Tong P, Diao L, Li L, Fan Y, Hoff J, Heymach JV, Wang J, Byers LA. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. Clin Cancer Res 23(20):6239-6253, 2017. e-Pub 2017. PMID: 28698200.
104. Byers LA, Horn L, Ghandi J, Kloecker G, Owonikoko T, Waqar SN, Krzakowski M, Cardnell RJ, Fujimoto J, Taverna P, Azab M, Camidge DR. A Phase 2, Open-label, Multi-center Study of Amuvatinib in Combination with Platinum Etoposide Chemotherapy in Platinum-refractory Small Cell Lung Cancer Patients. Oncotarget 8(46):81441-81454, 2017. e-Pub 2017. PMID: 29113403.
105. Cardnell RJ, Li L, Sen T, Bara R, Tong P, Fujimoto J, Ireland AS, Guthrie MR, Bheddah S, Banerjee U, Kalu NN, Fan YH, Dylla SJ, Johnson FM, Wistuba II, Oliver TG, Heymach JV, Glisson BS, Wang J, Byers LA. Protein Expression of TTF1 and cMYC Define Distinct Molecular Subgroups of Small Cell Lung Cancer with Unique Vulnerabilities to Aurora Kinase Inhibition, DLL3 Targeting, and Other Targeted Therapies. Oncotarget 8(43):73419-73432, 2017. e-Pub 2017. PMID: 29088717.
106. Valenzuela N, Soibam B, Li L, Wang J, Byers LA, Liu Y, Schwartz RJ, Stewart MD. HIRA Deficiency in Muscle Fibers Causes Hypertrophy and Susceptibility to Oxidative Stress. J Cell Sci 130(15):2551-2563, 2017. e-Pub 2017. PMID: 28600325.
107. Sen T, Tong P, Stewart CA, Cristea S, Valliani A, Shames DS, Redwood AB, Fan YH, Li L, Glisson BS, Minna JD, Sage J, Gibbons DL, Piwnica-Worms H, Heymach JV, Wang J, Byers LA. CHK1 Inhibition in Small Cell Lung Cancer Produces Single-agent Activity in Biomarker-defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer Res 77(14):3870-3884, 2017. e-Pub 2017. PMID: 28490518.
108. de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA. Phase I, Dose-Escalation, 2-Part Trial of Poly (ADP-Ribose) Polymerase Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discov 7(6):620-629, 2017. e-Pub 2017. PMID: 28242752.
109. Skinner HD, Giri U, Yang LP, Kumar M, Liu Y, Story MD, Pickering CR, Byers LA, Williams MD, Wang J, Shen L, Yoo SY, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV. Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. Clin Cancer Res 23(11):2713-2722, 2017. e-Pub 2017. PMID: 28476872.
110. Kim J, Hu Z, Cai L, Li K, Choi E, Faubert B, Bezwada D, Rodriguez-Canales J, Villalobos P, Lin YF, Ni M, Huffman KE, Girard L, Byers LA, Unsal-Kacmaz K, Peña CG, Heymach JV, Wauters E, Vansteenkiste J, Castrillon DH, Chen BPC, Wistuba I, Lambrechts D, Xu J, Minna JD, DeBerardinis RJ. CPS1 Maintains Pyrimidine Pools and DNA Synthesis in KRAS/LKB1-mutant Lung Cancer Cells. Nature 546(7656):168-172, 2017. e-Pub 2017. PMID: 28538732.
111. Peng DH, Ungewiss C, Tong P, Byers LA, Wang J, Canales JR, Villalobos PA, Uraoka N, Mino B, Behrens C, Wistuba II, Han RI, Wanna CA, Fahrenholtz M, Grande-Allen KJ, Creighton CJ, Gibbons DL. ZEB1 Induces LOXL2-mediated Collagen Stabilization and Deposition in the Extracellular Matrix to Drive Lung Cancer Invasion and Metastasis. Oncogene 36(14):1925-1938, 2017. e-Pub 2017. PMID: 27694892.
112. Kakumu T, Sato M, Goto D, Kato T, Yogo N, Hase T, Morise M, Fukui T, Yokoi K, Sekido Y, Girard L, Minna JD, Byers LA, Heymach JV, Coombes KR, Kondo M, Hasegawa Y. Identification of Proteasomal Catalytic Subunit PSMA6 as a Therapeutic Target for Lung Cancer. Cancer Sci 108(4):732-743, 2017. e-Pub 2017. PMID: 28165654.
113. Stewart CA, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu K, Shen Y, Glisson BS, Wistuba I, Heymach JV, Gibbons DL, Wang J, Byers LA. Dynamic Variations in Epithelial-to-mesenchymal Transition (EMT), ATM, and SLFN11 Govern Response to PARP Inhibitors and Cisplatin in Small Cell Lung Cancer. Oncotarget 8(17):28575-28587, 2017. e-Pub 2017. PMID: 28212573.
114. Federico L, Chong Z, Zhang D, McGrail DJ, Zhao W, Jeong KJ, Vellano CP, Ju Z, Gagea M, Liu S, Mitra S, Dennison JB, Lorenzi PL, Cardnell R, Diao L, Wang J, Lu Y, Byers LA, Perou CM, Lin SY, Mills GB. A Murine Preclinical Syngeneic Transplantation Model for Breast Cancer Precision Medicine. Sci Adv 3(4):e1600957, 2017. e-Pub 2017. PMID: 28439535.
115. Research Network CGA. Integrated Genomic and Molecular Characterization of Cervical Cancer. Nature 543(7645):378-384, 2017. e-Pub 2017. PMID: 28112728.
116. Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA, Davies MA, Deng W, Gopal YN, Chen G, von Euw EM, Slamon D, Conklin D, Heymach JV, Gazdar AF, Minna JD, Myers JN, Lu Y, Mills GB, Liang H. Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell 31(2):225-239, 2017. e-Pub 2017. PMID: 28196595.
117. Balaji K, Vijayaraghavan S, Diao L, Tong P, Fan Y, Carey JP, Bui TN, Warner S, Heymach JV, Hunt KK, Wang J, Byers LA, Keyomarsi K. AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. (**featured article on cover of journal). Mol Cancer Res 15(1):45-58, 2017. e-Pub 2017. PMID: 27671334.
118. Frumovitz M, Munsell MF, Burzawa JK, Byers LA, Ramalingam P, Brown J, Coleman RL. Combination Therapy with Topotecan, Paclitaxel and Bevacizumab Improves Progression-free Survival in Recurrent Small Cell Neuroendocrine Carcinoma of the Cervix. Gynecol Oncol 144(1):46-50, 2017. e-Pub 2017. PMID: 27823771.
119. Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR, Investigators S. Rovalpituzumab Tesirine, a DLL3-targeted Antibody-drug Conjugate, in Recurrent Small-cell Lung Cancer: A First-in-human, First-in-class, Open-label, Phase 1 Study. Lancet Oncol 18(1):42-51, 2017. e-Pub 2017. PMID: 27932068.
120. Tsao, A, Wistuba, II, Xia, D, Byers, LA, Diao, L, Wang, J, Papadimitrakopoulou, VA, Tang, X, Lu, W, Kadara, HN, Grigoryev, DN, Selvan, ME, Gümüş, ZH, Tan, Z, Zhang, S, Nilsson, M, Heymach, JV. Germline and somatic smoothened mutations in non-small-cell lung cancer are potentially responsive to hedgehog inhibitor vismodegib. JCO Precision Oncology 2017(1):1-10, 2017. e-Pub 2017. PMID: 35172522.
121. Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 34(30):3638-3647, 2016. e-Pub 2016. PMID: 27480147.
122. Skinner HD, Giri U, Yang L, Woo SH, Story MD, Pickering CR, Byers LA, Williams MD, El-Naggar A, Wang J, Diao L, Shen L, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV. Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV Negative Head and Neck Cancer. Clin Cancer Res 22(18):4643-50, 2016. e-Pub 2016. PMID: 27036135.
123. Chen L, Yi X, Goswami S, Ahn YH, Roybal JD, Yang Y, Diao L, Peng D, Peng D, Fradette JJ, Wang J, Byers LA, Kurie JM, Ullrich SE, Qin FX, Gibbons DL. Growth and Metastasis of Lung Adenocarcinoma is Potentiated by BMP4-mediated Immunosuppression. Oncoimmunology 5(11):e1234570, 2016. e-Pub 2016. PMID: 27999749.
124. Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C, Rodriguez JC, Hwu P, Wistuba II, Heymach JV, Gibbons DL. Epithelial-mesenchymal Transition is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res 22(14):3630-42, 2016. e-Pub 2016. PMID: 26851185.
125. Frumovitz M, Burzawa JK, Byers LA, Lyons YA, Ramalingam P, Coleman RC, Brown J. Sequencing of Mutational Hotspots in Cancer-Related Genes in Small Cell Neuroendocrine Cervical Cancer. Gynecol Oncol 141(3):588-91, 2016. e-Pub 2016. PMID: 27079212.
126. Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, Imielinski M, Hu X, Ling S, Akbani R, Rosenberg M, Cibulskis C, Ramachandran A, Collisson EA, Kwiatkowski DJ, Lawrence MS, Weinstein JN, Verhaak RG, Wu CJ, Hammerman PS, Cherniack AD, Getz G, Research Network CGA, Artyomov MN, Schreiber R, Govindan R, Meyerson M. Distinct Patterns of Somatic Genome Alterations in Lung Adenocarcinomas and Squamous Cell Carcinomas. Nat Genet 48(6):607-16, 2016. e-Pub 2016. PMID: 27158780.
127. Ferrarotto R, Goonatilake R, Young Yoo S, Tong P, Giri U, Peng S, Minna J, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, Heymach JV, Wang J, Byers LA, Johnson FM. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Clin Cancer Res 22(7):1674-86, 2016. e-Pub 2016. PMID: 26597303.
128. Cardnell RJ, Feng Y, Mukherjee S, Diao L, Tong P, Stewart CA, Masrorpour F, Fan Y, Nilsson M, Shen Y, Heymach JV, Wang J, Byers LA. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer. PLoS One 11(4):e0152584, 2016. e-Pub 2016. PMID: 27055253.
129. Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, Heymach JV, Weinstein JN, Coombes KR, Wang J, Byers LA. A Patient-derived, Pan-cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial to Mesenchymal Transition. Clin Cancer Res 22(3):609-20, 2016. e-Pub 2016. PMID: 26420858.
130. Kundu ST, Byers LA, Peng DH, Roybal JD, Diao L, Wang J, Tong P, Creighton CJ, Gibbons DL. The miR-200 Family and the miR-183~96 ~182 Cluster Target Foxf2 to Inhibit Invasion and Metastasis in Lung Cancers. Oncogene 35(2):173-186, 2016. e-Pub 2016. PMID: 25798833.

Review Articles

1. Qin K, Gay CM, Byers LA, Zhang J. The Current and Emerging Immunotherapy Paradigm in Small Cell Lung Cancer. Nature Cancer, 2025. e-Pub 2025. PMID: 40473974.
2. Shields MD, Chiang AC, Byers LA. Top advances of the year: Small cell lung cancer. Cancer 131(6):e35770, 2025. e-Pub 2025. PMID: 40040254.
3. Megyesfalvi Z, Gay CM, Popper H, Pirker R, Ostoros G, Heeke S, Lang C, Hoetzenecker K, Schwendenwein A, Boettiger K, Bunn PA, Renyi-Vamos F, Schelch K, Prosch H, Byers LA, Hirsch FR, Dome B. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin 73(6):620-652, 2023. e-Pub 2023. PMID: 37329269.
4. Moliner L, Zhang B, Lamberti G, Ardizzoni A, Byers LA, Califano R. Novel therapeutic strategies for recurrent SCLC. Crit Rev Oncol Hematol 186:104017, 2023. e-Pub 2023. PMID: 37150311.
5. Concannon K, Morris BB, Gay CM, Byers LA. Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. Mol Cell 83(5):660-680, 2023. e-Pub 2023. PMID: 36669489.
6. Zhang B, Ramkumar K, Cardnell RJ, Gay CM, Stewart CA, Wang WL, Fujimoto J, Wistuba II, Byers LA. A Wake-up Call for Cancer DNA Damage: The Role of Schlafen 11 (SLFN11) Across Multiple Cancers. Br J Cancer 125(10):1333-1340, 2021. e-Pub 2021. PMID: 34294893.
7. Cargill KR, Hasken WL, Gay CM, Byers LA. Alternative Energy: Breaking Down the Diverse Metabolic Features of Lung Cancers. Front Oncol 11:757323, 2021. e-Pub 2021. PMID: 34745994.
8. Shah PA, Huang C, Li Q, Kazi SA, Byers LA, Wang J, Johnson FM, Frederick MJ. Notch1 signaling in head and neck squamous cell carcinoma. Cells 9(12):2677, 2020. e-Pub 2020. PMID: 33322834.
9. Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba II, Tripathy D, Bernatchez C, Byers LA, Chang JT, Contreras A, Lim B, Parra ER, Roarty EB, Wang J, Yang F, Barton M, Rosen JM, Mani SA. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers (Basel) 11(5), 2019. e-Pub 2019. PMID: 31137625.
10. Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, Oliver TG, Quaranta V, Sage J, Thomas RK, Vakoc CR, Gazdar AF. Molecular Subtypes of Small Cell Lung Cancer: A Synthesis of Human and Mouse Model Data. Nat Rev Cancer 19(5):289-297, 2019. e-Pub 2019. PMID: 30926931.
11. Sen, T, Gay, CM, Byers, LA. Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. Translational Lung Cancer Research 7(1):50-68, 2018. e-Pub 2018. PMID: 29535912.
12. Lu Y, Ling S, Hegde AM, Byers LA, Coombes K, Mills GB, Akbani R. Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. Semin Oncol 43(4):476-83, 2016. e-Pub 2016. PMID: 27663479.

Abstracts

1. Stewart C, Ramkumar K, Wang R, Yang Y, Zhang B, Halliday A, Xi Y, Diao L, Wang Q, Duarte A, Li P, Tanimoto A, Serrano A, Vykoukal J, Bose M, Karacosta L, Soto LS, Hanash S, Wang J, Heymach JV, Byers LA, Gay CM. Surface targeting strategies to overcome heterogeneity associated with treatment resistance in small cell lung cancer (SCLC). 2025 IASLC World Conference on Lung Cancer, 2025.
2. Ramkumar K, Stewart C, Li P, Wang R, Ibrahim AH, Diao L, Shen L, Xi Y, Heeke S, Wang J, Zhang B, Byers LA, Gay CM. HER2- and TROP2-directed antibody drug conjugates show potent anti-tumor activities in small cell lung cancer. 2025 IASLC World Conference on Lung Cancer, 2025.
3. Zhang B, Shah KB, Parma M, Wang K, Singhi EK, Lewis W, Rivera M, Altan M, Pozadzides J, Le X, Vokes N, Fossella F, O’Brien B, Wang C, Tom MC, Beckham T, Swanson T, Bronk J, Lin SH, Vega MF, Jacome J, Halliday A, Negrao M, Zhang J, Gibbons DL, Heymach JV, Byers LA#, Gay CM#. Rapid intracranial response with tarlatamab in patients with untreated brain metastases from small cell lung cancer-- a real-world case series. 2025 Annual Lung Cancer SPORE Meeting, 2025.
4. Tanimoto A, Ramkumar K, Stewart C, Zhang B, Concannon K, Cardnell RJ, Li S, Wang Q, Wang J, Gay CM, Byers LA. The impact of targeting TRAF2 and NCK-interacting protein kinase (TNIK) on anti-tumor effect and tumor immune environment in c-MYC-high small cell lung cancer. 2025 Annual Lung Cancer SPORE Meeting, 2025.
5. Stewart C, Ramkumar K, Wang R, Yang Y, Zhang B, Halliday A, Xi Y, Diao L, Wang Q, Duarte A, Li P, Tanimoto A, Serrano A, Vykoukal J, Bose M, Karacosta L, Soto LS, Hanash S, Wang J, Heymach JV, Byers LA, Gay CM. Combination surface targeting strategies in relapsed small cell lung cancer (SCLC) to overcome intratumoral heterogeneity associated with treatment resistance. 2025 Annual Lung Cancer SPORE Meeting, 2025.
6. Ramkumar K#, Stewart CA#, Li P, Wang R, Ibrahim AH, Wang Q, Xi Y, Shen L, Diao L, Heeke S, Wang J, Zhang B, Byers LA, Gay CM. Antitumor activities of HER2- and TROP2-directed antibody drug conjugates in recalcitrant pulmonary high-grade neuroendocrine carcinomas. 2025 Annual Lung Cancer SPORE Meeting, 2025.
7. Ramkumar K, Stewart CA, Yang Y, Zhang B, Wang Q, Xi Y, Wang R, Serrano AG, Solis Soto LM, Wang J, Heymach JV, Gay CM, Byers LA. AXL-directed surface targeting approaches in recalcitrant pulmonary high-grade neuroendocrine carcinomas. AACR Annual Meeting 2025, 2025.
8. Stewart CA, Ramkumar K, Wang R, Yang Y, Zhang B, Halliday A, Xi Y, Diao L, Wang Q, Duarte A, Li P, Tanimoto A, Serrano A, Vykoukal J, Bose M, Karacosta L, Soto LS, Hanash S, Wang J, Heymach JV, Byers LA, Gay CM. Combination surface targeting strategies in relapsed small cell lung cancer (SCLC) to overcome intratumoral heterogeneity associated with treatment resistance. 2025 IASLC SCLC Hot Topic Meeting, 2025.
9. Stewart CA, Ramkumar K, Wang R, Yang Y, Zhang B, Xi Y, Diao L, Wang Q, Duarte A, Li P, Tanimoto A, Serrano A, Vykoukal J, Bose M, Karacosta L, Soto LS, Hanash S, Wang J, Heymach JV, Byers LA, Gay CM. Combination surface targeting strategies in relapsed small cell lung cancer (SCLC) to overcome intratumoral heterogeneity associated with treatment resistance. AACR Annual Meeting 2025, 2025.
10. Ramkumar K#, Stewart CA#, Li P, Wang R, Ibrahim AH, Wang Q, Xi Y, Shen L, Diao L, Wang J, Zhang B, Byers LA, Gay CM. Antitumor activities of HER2- and TROP2-directed antibody drug conjugates in recalcitrant pulmonary high-grade neuroendocrine carcinomas. 2025 IASLC SCLC Hot Topic Meeting, 2025.
11. Wang R, Stewart C, Duarte A, Yang Y, Halliday A, Hartsfield P, Napoleon H, Tran H, Zhang J, Zhang B, Gay CM, Byers LA. Establishing preclinical models and profiling liquid biopsies from small cell lung cancer (SCLC) patients treated with surface targeting therapies. 5th Annual THNMO Research Retreat, 2025.
12. Ramkumar K, Stewart C, Tanimoto A, Wang Q, Xi Y, Shen L, Wang R, Halliday AJ, Serrano AG, Soto LS, Wang J, Gay CM, Byers LA. Targeting vulnerabilities in drug-resistant SCLC persisters through AXL inhibition. 5th Annual THNMO Research Retreat, 2025.
13. Stewart C, Ramkumar K, Wang R, Yang Y, Zhang B, Halliday A, Xi Y, Diao L, Wang Q, Duarte A, Li P, Tanimoto A, Serrano A, Vykoukal J, Bose M, Karacosta L, Soto LS, Hanash S, Wang J, Heymach JV, Byers LA, Gay CM. Combination surface targeting strategies in relapsed small cell lung cancer (SCLC) to overcome intratumoral heterogeneity associated with treatment resistance. 5th Annual THNMO Research Retreat, 2025.
14. Blais N, Cournoyer G, Dionne J, Labbe C, Gaboury L, Trinh VQ, Burnier JV, Bartolomucci A, Viau E, Laurin J, Filion M, Jolivet J, Byers LA. A phase II trial to evaluate the epithelial-to-mesenchymal (EMT) inhibitor sotevtamab combined with docetaxel in patients with metastatic non-small cell lung cancer following failure of primary chemoimmunotherapy. 2024 ASCO Annual Meeting, 2024.
15. Chandana SR, Choudhury NJ, Dowlati A, Chiang AC, Garmezy B, Kim J, Byers LA, Ahn M, Kim TM, Kim Y, Han J, Bar J, Zha J, Henner W, Robinson R, KOHLHAPP F, Hingorani P, Papadopoulos KP. First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors. 2024 ASCO Annual Meeting, 2024.
16. Zhen DB, Moseley A, Chiorean E, Burgess EF, Swisher EM, Gay CM, Byers LA, Wistuba II, Mahdi H, Starr JS, Othus M, Chae YK, Kurzrock R. SWOG S2012: Randomized phase II/III trial of first line platinum (P)/etoposide (E) with or without atezolizumab (NSC #783608) in patients with advanced or metastatic poorly differentiated extrapulmonary neuroendocrine carcinomas (NEC). 2024 ASCO Annual Meeting, 2024.
17. Owonikoko TK, Byers LA, Cheng Y, Hayashi H, Paz-Ares LG, Perol M, Turner J, Qian M, Garcia CR, Godard J, Rudin CM. IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician’s choice (TPC) in relapsed small cell lung cancer (SCLC). 2024 ASCO Annual Meeting, 2024.
18. Gay CM, Owonikoko TK, Byers LA, Choudhury NJ, Ahmed S, Cain Z, Qian X, Brentnall M, Heeke S, Poi M, Wu S, Rudin CM. Multidimensional analysis of B7 homolog 3 (B7-H3) RNA expression in small-cell lung cancer (SCLC) molecular subtypes. 2024 ASCO Annual Meeting, 2024.
19. Byers LA. Subtype Classification of small cell lung cancer(SCLC) tissues using the Epicheck methylation sensitive restriction-based PCR platform. AACR Annual Meeting 2024, 2024.
20. Tanimoto A, Ramkumar K, Stewart C, Zhang B, Cardnell RJ, Li S, Wang Q, Wang J, Gay CM, Byers LA. The impact of targeting TRAF2 and NCK-interacting protein kinase on anti-tumor effect and tumor immune environment in cMYC-high small cell lung cancer. AACR Annual Meeting 2024, 2024.
21. Zhang B, Ibrahim AH, Stewart C, Serrano A, Solis LM, Wang W, Ramkumar K, Cardnell RJ, Wang R, Jr AD, Shen L, Xi Y, Wang Q, Diao L, Wang J, Byers LA, Gay CM. Acitivity of HER2-and TROP2-antibody drug conjugates (ADCs) in small cell lung cancer (SCLC) models with SLFN11 as a predictive biomarker. AACR Annual Meeting 2024, 2024.
22. Stewart A, Groves SM, Wang R, Ramkumar K, Xi Y, Diao L, Serrano AG, Tanimoto A, Victorian AM, Bhattacharyya S, Halliday A, Kalhor N, Soto LS, Rocha PD, Vokes N, Karacosta LG, Wang J, Heymach J, Quaranta V, Glisson B, Byers LA, Gay CM. YAP1 defines a highly plastic, persister cell population in small cell lung cancer (SCLC) following relapse. AACR Annual Meeting 2024, 2024.
23. Ibrahim AH, Zhang B, Stewart C, Serrano A, Solis LM, Wang W, Ramkumar K, Cardnell RJ, Wang R, Jr AD, Diao L, Xi Y, Wang J, Byers LA, Gay CM. Advancing personalized therapies for small cell lung cancer: Exploring HER2-targeting antibody-drug conjugates (ADCs) and SLFN11 biomarker insights. 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, 2023.
24. Elamin YY, Gandhi S, Saad M, Rehmani S, Antonoff MB, Gibbons DL, Le X, Negrao MV, Lam V, Byers L, Cascone T, Blumenschein G, Chang J, Vaporciyan A, Liao Z, Swisher S, Yin J, Zhang P, Wu J, Heymach JV. BRIGHTSTAR: A phase II trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naïve ALK-rearranged oligo- and poly-metastatic NSCLC. 2023 ASCO Annual Meeting, 2023.
25. Abdel Karim NF, Miao J, Reckamp KL, Gay CM, Byers LA, Zhao Y, Redman MW, Carrizosa DR, Wang WL, Petty WJ, Mehta K, Faller BA, Agamah ES, Kasbari SS, Malisetti RK, Kumar A, Schallenkamp J, Alluri KC, Gray JE, Kelly K. SWOG S1929: Phase II Randomized Study of Maintenance Atezolizumab (A) Versus Atezolizumab + Talazoparib (AT) in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC). 2023 ASCO Annual Meeting, 2023.
26. Vykoukal J, Kato T, Katayama H, Stewart A, Irajizad E, Cai Y, Hsiao F, Dennison JB, Ostrin EJ, Tran HT, Gay CM, Byers LA, Fahrmann J, Hanash SM. Integrated workflows for mass-spectrometry based profiling of cancer cell derived extracellular vesicles in biofluids and tissues. American Society for Mass Spectrometry (ASMS), 2023.
27. Heeke S, Gay CM, Estecio MR, Tran HT, Morris BB, Zhang B, Tang X, Raso MG, Rocha P, Arriola E, Hofman P, Kopparapu P, Lovly CM, Concannon K, Xi Y, Diao L, Wang Q, Wang J, Byers LA, Heymach J. Analysis of tumor- and circulating-free DNA methylation to identify clinically relevant small cell lung cancer subtypes. 2023 ASCO Annual Meeting, 2023.
28. Heeke S, Gandhi S, Tran HT, Lam V, Byers LA, Gibbons DL, Gay CM, Altan M, Antonoff MB, Le X, Tu J, Pek M, Poh J, Ngew KC, Tsao A, Cascone T, Negrao M, Jr BG, Heymach JV, Elamin YY. Longitudinal tracking of ALK-positive lung cancer from plasma using circulating-tumor RNA and circulating-tumor DNA in the BRIGHTSTAR clinical trial. 2023 ASCO Annual Meeting, 2023.
29. Tanimoto A, Cardnell RJ, Morris BB, Ramkumar K, Li S, Wang Q, Stewart CA, Gay CM, Wang J, Byers LA. TNIK inhibition as a novel therapeutic in c-Myc high/TTF1 low SCLC. AACR Annual Meeting 2023, 2023.
30. Stewart CA, Diao L, Xi Y, Wang R, Ramkumar K, Rodriguez B, Morris BB, Shen L, Zhang B, Yang Y, Tanimoto A, Soto LS, Rocha PD, Vokes N, Gibbons D, Frumovitz M, Fujimoto J, Wang J, Glisson B, Byers LA, Gay CM. Emergence of YAP1-positive cell populations at SCLC relapse. 2023 IASLC SCLC Hot Topics Meeting, 2023.
31. Concannon K, Heeke S, Sahu M, Tang X, Sasaki K, Patel S, Raso G, Tran H, Gay CM, Byers LA. Clinical and transcriptomic analysis demonstrates improved survival and unique gene expression signatures among SCLC arising in patients with minimal tobacco use. AACR Annual Meeting 2023, 2023.
32. Morris BB, Nabet B, Shames D, Heeke S, Gay CM, Wang J, Zhang J, Heymach JV, Byers LA. Comprehensive DNA Repair Landscape Analysis Reveals Novel Small Cell Lung Cancer Biology. AACR Annual Meeting 2023, 2023.
33. Stewart CA, Diao L, Xi Y, Wang R, Ramkumar K, Rodriguez BL, Morris BB, Shen L, Zhang B, Yang Y, Tanimoto A, Novegil VY, Soto LS, Rocha PD, Vokes N, Gibbons D, Frumovitz M, Fujimoto J, Wang J, Glisson B, LA Byers LA, CM Gay CM. YAP1 in relapsed pulmonary high-grade neuroendocrine carcinomas (NEC) is associated with CDKN2A loss, intact RB1, EMT and therapeutic vulnerability to MEK1 and CDK4/6 inhibition. AACR Annual Meeting 2023, 2023.
34. Zhang B, Yang Y, Stewart CA, Ramkumar K, Wang R, Cardnell RJ, Diao L, Wang Q, Wang J, Byers LA, Gay CM, Heymach JV. Subtype-specific targeting of cell surfaceome with CAR T therapies in small cell lung cancer. AACR Annual Meeting 2023, 2023.
35. Ramkumar R, Stewart CA, Tanimoto A, Wang Q, Xi Y, Morris BB, Wang R, Shen L, Cardnell RJ, Wang J, Gay CM, Byers LA. Combined inhibition of AXL and ATR enhances replication stress, cell death and immune responses in small cell lung cancer. AACR Annual Meeting 2023, 2023.
36. Zhang B, Concannon K, Stewart CA, Lewis W, Xi Y, Cardnell R, Morris BB, Sasaki K, Lopez ER, Rinsurongkawong W, Tran H, Heeke S, Zhang J, Wang J, Heymach JV, Gay CM, Byers LA, Le X. Clinicogenomic characteristics of EGFR mutant non-small cell lung cancer transformation to small cell lung cancer. Texas Lung Cancer Conference, 2023.
37. Nabet BY, Hamidi H, Banchereau R, Morris S, Adler L, Srivastava MK, Patil NS, Gay CM, Minna J, Chan JM, Rudin CM, Byers LA, Liu SV, Reck M, Shames DS. Small cell lung cancer molecular subtypes and vulnerability to immune checkpoint blockade. SITC Annual Meeting, 2022.
38. Byers LA, Heymach JV, Gibbons DL, Zhang J, Chiappori A, Rasmussen E, Decato BE, Smit MD, Sadraei NH. A phase 1 study of AMG 119, a DLL3-targeting, chimeric antigen receptor (CAR) T cell therapy, in relapsed/refractory small cell lung cancer (SCLC). SITC Annual Meeting, 2022.
39. Stewart CA, Xi Y, Wang R, Ramkumar K, Novegil VY, Frumovitz M, Wang J, Byers LA, Gay CM. Transcriptional diversity of emerging cell populations in refractory small cell lung cancer biopsies and xenografts. 2022 IASLC World Conference on Lung Cancer, 2022.
40. Byers LA, Gold KA, Peguero JA, Johnson ML, Nieva JJ, Harb WA, Chiappori A, Rybkin II, Strauss JF, Gerber DE. Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update. 2022 ASCO Annual Meeting, 2022.
41. Elamin YY, Negrao MV, Fossella FV, Byers LA, Zhang J, Gay CM, Tu JC, Pozadzides JV, Tran HT, Lu C, Feng L, Spelman AR, Blumenschein GR, Tsao AS, Heymach J. Results of a phase 1b study of osimertinib plus sapanisertib or alisertib for osimertinib-resistant EGFR mutant non-small cell lung cancer (NSCLC). 2022 ASCO Annual Meeting, 2022.
42. Zhen DB, Mayerson E, Chiorean E, Burgess EF, Swisher EM, Gay CM, Byers LA, Wistuba II, Mahdi H, Das S, Starr JS, Othus M, Chae YK, Kurzrock R. SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC). 2022 ASCO Annual Meeting, 2022.
43. Zhang B, Birer SR, Dvorkin M, Shruti J, Byers L. New Therapies and Biomarkers: Are We Ready for Personalized Treatment in Small Cell Lung Cancer?. 2022 ASCO Annual Meeting, 2022.
44. Stewart CA, Xi Y, Wang R, Frumovitz MM, Wang J, Byers LA, Gay CM. Defining the transcriptional complexity of persister cell populations in relapsed small cell lung cancer patient biopsies. AACR Annual Meeting 2022, 2022.
45. Yuca E, Evans K, Akcakanat A, Raso G, Rizvi YQ, Yang F, Byers L, Damodaran S, Daisuke O, Meric-Bernstam F. Anti-tumor activity and biomarker analysis for datopotamab deruxtecan in breast cancer PDX models. AACR Annual Meeting 2022, 2022.
46. Lima CF, Rocha PS, Fujimoto J, Stewart A, Cardnell R, Lu W, Khan K, Sable B, Ellison AR, Wistuba II, Gay CM, Kalhor N, Byers LA, Solis-Soto LM. Delta-like ligand 3 immunohistochemical expression landscape in high-grade lung neuroendocrine tumors. AACR Annual Meeting 2022, 2022.
47. Ramkumar K, Tanimoto A, Stewart CA, Shen L, Wang Q, Cardnell RJ, Wang J, Gay CM, Byers LA. Combined inhibition of AXL and ATR enhances cell death and immune response in small cell lung cancer. AACR Annual Meeting 2022, 2022.
48. Le X, Wang R, Vokes N, Elamin Y, Kalhor N, McGrail D, Xi Y, Treviño III S, Hong L, Du R, Blumenschein G, Gay C, Negrao M, Altan M, Tran H, Hu L, Wang J, Heeke S, Nilsson M, Robichaux J, Dang M, Han G, Byers LA, Tsao A, Sepesi B, Bernatchez C, Zhang J, Wang L, Heymach J. Enhanced lineage plasticity in RTK-independent TKI-resistant EGFR-mutant NSCLC. AACR Annual Meeting 2022, 2022.
49. Nelson BE, Roszik J, Janku F, Hong D, Kato S, Naing A, Piha-Paul S, Fu S, Tsimberidou A, Cabanillas M, Busaidy N, Javle M, Byers L, Heymach J, Meric-Bernstam F, Subbiah V. B-Raf V600E harboring non-melanoma cancers treated with Vemurafenib monotherapy and in combination with Everolimus/Sorafenib/Crizotinib/Paclitaxel+ Carboplatin: A pooled analysis of five phase 1/2 studies. AACR Annual Meeting 2022, 2022.
50. Xie M, Chugh P, Broadhurst H, Lai Z, Whitston D, Paz-Ares L, Gay C, Byers L, Rudin CM, Stewart R, Barrett JC, Shrestha Y. Durvalumab (D) + platinum-etoposide (EP) in 1L extensive-stage small-cell lung cancer (ES-SCLC): Exploratory analysis of SCLC molecular subtypes in CASPIAN. AACR Annual Meeting 2022, 2022.
51. Kundu K, Cardnell RJ, Diao L, Shen L, Stewart CA, Ramkumar K, Gay CM, Wang J, Byers LA. Characterizing natural killer cell cytotoxicity in small cell lung cancer subtypes. AACR Annual Meeting 2022, 2022.
52. Heeke S, Gay CM, Estecio MR, Stewart A, Tran H, Zhang B, Tang X, Raso G, Concannon K, De Sousa LG, Lewis WE, Nilsson M, Xi Y, Diao L, Wang Q, Zhang J, Wang J, Wistuba II, Byers LA, Heymach JV. Use of DNA methylation from tumor and plasma to identify four major small cell lung cancer subtypes with distinct biology and therapeutic vulnerabilities. AACR Annual Meeting 2022, 2022.
53. Kornepati A, Murray C, Avalos B, Rogers C, Ramkumar K, Gupta H, Deng Y, Liu Z, Padron A, Vadlamudi R, Dray E, Zhao W, Sung P, Byers L, Curiel T. Depleting non-canonical, cell-intrinsic PD-L1 signals induces synthetic lethality to small molecule DNA damage response inhibitors in an immune independent and dependent manner 9(Suppl 2), 2021. e-Pub 2021.
54. Byers LA. Small Cell Lung Cancer: Are We Beginning to Impact Outcomes?. 2021 ASCO Annual Meeting Virtual, 2021.
55. Gordon M, Roszik J, Cabanillas ME, Hu MI, Lamki Busaidy N, Sherman SI, Dadu R, Gardner Grubbs E, Elamin YY, Cascone T, Byers LA, Blumenschein GR, Fossella FV, Naing A, Hong DS, Heymach J, Meric-Bernstam F, Subbiah V. Prognostic Factors in RET Dependent Cancers Treated with RET Inhibitors in Early Phase Clinical Trials | Poster Session. 2021 ASCO Annual Meeting Virtual, 2021.
56. Rimner A, Lai WVV, Califano R, Jabbour SK, Faivre-Finn C, Chul Cho B, Kato T, Yu J, Yu L, Zhao B, Pietanza MC, Byers LA. KEYLYNK-013: A Phase 3 Study of Pembrolizumab in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib versus Concurrent Chemoradiation Therapy in Patients with Newly Diagnosed Limited-stage SCLC. 2021 ASCO Annual Meeting Virtual, 2021.
57. Byers LA. Ph I/II Study of Oral Selective AXL Inhibitor Bemcentnib (BGB324) in Combination with Erlotinib in Patients with Advanced EGFRm NSCLC: End of Trial Update. 2021 ASCO Annual Meeting Virtual, 2021.
58. Cargill KR, Stewart CA, Park EM, Cardnell RJ, Fan YH, Wang Q, Diao L, Chan WK, Lorenzi PL, Wang L, Byers LA. Targeting MYC-enhanced Glycolysis in Small Cell Lung Cancer. AACR Annual Meeting 2021 Virtual, 2021.
59. Kundu K, Cardnell RJ, Shen L, Stewart CA, Cargill K, Gay CM, Wang J, Byers LA. Characterization of Lurbinectedin as a Single Agent and in Combinations with DNA Damage Response Inhibitor for the Treatment and Bio-marker Discovery of SCLC. AACR Annual Meeting 2021 Virtual, 2021.
60. Rocha P, Stewart CA, Parra E, Solis LM, Gay CM, Cardnell RJ, Uraoka N, Francisco-Cruz A, Dejima H, Xi Y, Diao L, Wang J, Negrao MV, Zhang J, Wistuba I, Gibbons DL, Byers LA. Multiplex Immunofluorescence (mIF) Reveals Differences in Tumor Immune Microenvironment between Molecularly-defined Subsets of Small Cell Lung Cancer. AACR Annual Meeting 2021 Virtual, 2021.
61. Zhang B, Stewart CA, Gay CM, Wang Q, Cardnell R, Fujimoto J, Fernandez L, Jendrisak A, Gilbertson C, Schonhoft J, Jones J, Anderson AKL, Wistuba II, Wang J, Wenstrup R, Byers LA. Detection of DNA Replication Blocker SLFN11 in Tumor Tissue and Circulating Tumor Cells to Predict Platinum and PARP Inhibitor Response in Small Cell Lung Cancer. AACR Annual Meeting 2021 Virtual, 2021.
62. Cargill KR, Stewart CA, Gay CM, Ramkumar K, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Diao L, Wang Q, Shen L, Xi Y, Kundu K, Minna JF, Gibbons DL, Wang J, Heymach JV, Byers LA. SARS-CoV-2 Infects Metabolically-primed Epithelial Cells in Lung Cancer Models. ESMO Virtual Congress 2020, Science Weekend, 2020.
63. Ramkumar K, Stewart CA, Gay CM, Cardnell RJ, Diao L, Wang Q, Shen L, Xi Y, Kundu S, Della Corte CM, Gibbons DL, Wang J, Heymach JV, Byers LA. Elevated AXL Expression Following SARS-CoV-2 Infection in Non-small Cell Lung Cancer. ESMO Virtual Congress 2020, Science Weekend, 2020.
64. Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu S, Diao L, Wang Q, Shen L, Xi Y, Della Corte CM, Kundu K, Gibbons DL, Wang J, Heymach JV, Byers LA. SARS-CoV-2 Infection Induces EMT-like Molecular Changes, Including ZEB1-mediated Repression of the Viral Receptor ACE2, in Lung Cancer Models. ESMO Virtual Congress 2020, Science Weekend, 2020.
65. Stewart CA, Gay CM, Xi Y, Sivajothi S, Fujimoto J, Hartsfield PM, Tran H, Swisher SG, Roth JA, Zhang J, Glisson B, Heymach JV, Wistuba I, Robson P, Wang J, Byers LA. Paired, Single-cell Profiling of Circulating Tumor Cell-derived Xenograft Models of Small Cell Lung Cancer Reveals Intratumoral Heterogeneity and Emergence of New Cell Clusters following Treatment Relapse. AACR Virtual Annual Meeting 2020, 2020.
66. Cargill KR, Gay CM, Cardnell RJ, Fan Y, Wang Q, Diao L, Wang J, Byers LA. Comprehensive Metabolic Profiling and Vulnerabilities to Metabolic Inhibitors among Small Cell Lung Cancer Subtypes. AACR Virtual Annual Meeting 2020, 2020.
67. Chen R, Jin Y, Li J, Zhang J, Fujimoto J, Lee WC, Hu X, Chen Y, Behrens C, Chow CW, Parra E, Little L, Gumbs C, Song X, Roarty E, Zhang J, Gibbons D, Heymach J, Lee JJ, William Jr W, Glisson B, Wistuba I, Futreal PA, Byers L, Reuben A, Chen M, Zhang J. Genomic and TCR Intratumor Heterogeneity of Small-Cell Lung Cancer by Multiregion Sequencing: An Association with Survival. IASLC 2019 World Conference on Lung Cancer, 2019.
68. Gay C, Diao L, Stewart C, Xi Y, Cardnell R, Swisher S, Roth J, Glisson B, Wang J, Heymach J, Byers LA. ASCL1, NEUROD1, and POU2F3 Drive Distinct Subtypes of Small Cell Lung Cancer with Unique Therapeutic Vulnerabilities. IASLC 2019 World Conference on Lung Cancer, 2019.
69. Byers LA, Chiappori A, Damiette Smit MA. Phase 1 Study of AMG 119, A Chimeric Antigen Receptor (CAR) T Cell Therapy Targeting DLL3, in Patients with Relapsed/refractory Small Cell Lung Cancer (SCLC). 2019 ASCO Annual Meeting, 2019.
70. Argiris A, Miao J, Cristea MC, Chen AM, Sands J, Decker RH, Gettinger SN, Daly ME, Faller BA, Albain KS, Yanagihara RH, Garland LL, Byers LA, Wang D, Koczywas M, Redman MW, Kelly K, Gandara DR. S1206: A Dose-finding Study Followed by a Phase II Randomized Placebo-controlled Trial of Chemoradiotherapy (CRT) with or without Veliparib in Stage III Non-small Cell Lung Cancer (NSCLC). 2019 ASCO Annual Meeting, 2019.
71. Owonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe T, Leighl NB, Al Baghdadi T, Lara P, Miao J, Kelly K, Ramalingam SS, Herbst RS, Papadimitrakopoulou V, Gandara DR. A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency (HRRD) Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study, S1400G). 2019 ASCO Annual Meeting, 2019.
72. Byers LA, Stewart A, Gay CA, Heymach JV, Fernandez L, Lu D, Rich R, Chu L, Wang Y, Dittamore R. SLFN11 and EZH2 Protein Expression and Localization in Circulating Tumor Cells to Predict Response or Resistance to DNA Damaging Therapies in Small Cell Lung Cancer. AACR Annual Meeting 2019, 2019.
73. Sen T, Della Corte CM, Milutinovic S, Diao L, Cardnell RJ, Hansen RJ, Strouse B, Hedrick MP, Hassig C, Wang J, Byers LA. Combination Treatment of the CHK1 Inhibitor, SRA737, and Low Dose Gemcitabine Demonstrates Profound Synergy with Anti-PDL1 Inducing Durable Tumor Regressions and Modulating the Immune Microenvironment in Small Cell Lung Cancer. AACR Annual Meeting 2019, 2019.
74. Gay CM, Diao L, Stewart CA, Xi Y, Cardnell RJ, Swisher SG, Roth JA, Glisson BS, Wang J, Heymach JV. Inter- and Intra-tumoral Variations in ASCL1, NEUROD1, and POU2F3 Transcriptional Programs Underlie Three Distinct Molecular Subtypes of Small Cell Lung Cancers. AACR Annual Meeting 2019, 2019.
75. Stewart CA, Gay CM, Xi Y, Fujimoto J, Kalhor N, Hartsfield PM, Tran H, Fernandez L, Lu D, Wang Y, Dittamore R, Zhang J, Swisher SG, Roth JA, Oliver TG, Heymach JV, Wistuba II, Glisson BS, Robson P, Wang J, Byers LA. Single-cell Analyses Reveal Increasing Intratumoral Heterogeneity as an Essential Component of Treatment Resistance in Small Cell Lung Cancer. AACR Annual Meeting 2019, 2019.
76. Ramkumar K, Tong P, Fan Y, Peng D, Heymach JV, Gibbons DL, Wang J, Byers LA. Targeting AXL Sensitizes Non-small Cell Lung Cancer to ATR Inhibitors by Enhancing Replication Stress. AACR Annual Meeting 2019, 2019.
77. Sen T, Rodriguez BL, Chen L, Morikawa N, Fujimoto J, Diao L Fan Y, Wang J, Glisson BS, Wistuba I, Sage J, Heymach JV, Gibbons D, Byers LA. Targeting DNA Damage Response Promotes Anti-tumor immunity through STING-mediated T-cell Activation in Small Cell Lung Cancer. 33rd Annual Meeting Society for Immunotherapy of Cancer (SITC), 2018.
78. Della Corte CM, Sen T, Diao L, Ramkumar K, Gay CM, Tong P, Fan YH, Cardnell RJ, Gibbons D, Heymach JV, Wang J, Byers LA. Cisplatin Treatment Induces Anti-tumor Immune Response in NSCLC by Activation of the Innate Immune Response Pathway. 33rd Annual Meeting Society for Immunotherapy of Cancer (SITC), 2018.
79. Oliver TG, Mollaoglu G, Chalishazar M, Huang F, Guthrie M, Bohm S, Breagelmann J, Sen T, Byers L, Johnson J, Wechsler-Reya R, Gazdar A, Deberardinis R, Sos ML. Genetic Mouse Models (GEMMS). IASLC 19th World Conference on Lung Cancer (WCLC 2018), 2018.
80. Tran HT, Lam VK, Vasquez ME, Hong L, Colen R, Elshafeey NA, Hassan ISA, Prado EA, Papadimitrakopoulou VA, Blumenschein GR, Carter BW, Simon GR, Byers L, Altan M, Elamin YY, Lanman RB, Raymond VM, Tsao AS, Gibbons DL, Fossella F, Zhang J, Heymach JV. Clinical Evaluation of Plasma-Based (cfDNA) Genomic Profiling in Over 1,000 Patients with Advanced Non-Small Cell Lung Cancer. IASLC 19th World Conference on Lung Cancer (WCLC 2018), 2018.
81. Goto D, Tanaka I, Sato M, Kato T, Miyazawa A, Hase T, Morise M, Sekido Y, Girard L, Minna JD, Byers L, Heymach JV, Coombes KR, Kondo M, Hasegawa Y. eIF2β, A Subunit of Translation-Initiation Factor EIF2, as a Potential Therapeutic Target for Non-Small Cell Lung Cancer. IASLC 19th World Conference on Lung Cancer (WCLC 2018), 2018.
82. Byers L, Gold K, Peguero J, Johnson ML, Nieva J, Harb WA, Chiappori AA, Strauss J, Gerber DE. Ph I/II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Erlotinib in pts with EGFRm NSCLC. IASLC 19th World Conference on Lung Cancer (WCLC 2018), 2018.
83. Owonikoko T, Dahlberg S, Sica GL, Poirier J, Byers L, Rudin CM, Wistuba II, Ramalingam SS. SLFN11 Expression and Efficacy of PARP Inhibitor Therapy in Extensive Stage Small Cell Lung Cancer: ECOG-ACRIN 2511 Study. IASLC 19th World Conference on Lung Cancer (WCLC 2018), 2018.
84. Stewart CA, Gay CM, Xi Y, V S, Fujimoto J, Tong P, Diao L, Li L, Bolisetty M, Kalhor N, Lawson P, Vasquez M, Tran H, Wistuba II, Glisson B, Zhang J, Swisher SG, Roth JA, Heymach JV, Robson P, Wang J, Byers LA. Single-cell Profiling of Small Cell Lung Cancer Circulating Tumor Cell-derived Xenograft Models Reveals Intratumoral Heterogeneity Among Mediators of Chemoresistance. AACR Annual Meeting 2018, 2018.
85. Gay CM, Tong P, Li L, Stewart CA, Sen T, Glisson BS, Heymach JV, Wang J, Byers LA. ATR Inhibitors are Active as Single Agents and in Combination with PARP1 and ATM Inhibitors in Molecularly Distinct Subsets of Small Cell Lung Cancer Models. AACR Annual Meeting 2018, 2018.
86. Negrao MV, Tang M, Jin Y, Chen Y, Hu X, Tang H, Xu H, Quek K, Zhang J, Mao X, Song X, Heymach JV, Wistuba I, Byers LA, Glisson BS, Futreal A, Chen M, Zhang J. Exome Sequencing of Paired Primary and Relapsed Small Cell Lung Cancers Reveals Increased Copy Number Aberration Complexity to be Associated with Disease Relapse. AACR Annual Meeting 2018, 2018.
87. Sato M, Kakumu T, Goto D, Kato T, Yogo N, Hase T, Morise M, Fukui T, Yokoi K, Sekido Y, Girard L, Minna J, Byers L, Heymach JV, Coombes K, Kondo M, Hasegawa Y. Identification of Proteasomal Catalytic Subunit PSMA6 as a Therapeutic Target for Lung Cancer through a Pooled shRNA Screen. IASLC 18th World Conference on Lung Cancer, 2017.
88. Suzuki R, Lin SH, Wei X, Allen PK, Welsh LA, Byers LA, Komaki R. Outcome Based on Baseline Total Lymphocyte Count & Neutrophil-To-Lymphocyte Ratio in Extensive Stage Small-Cell Lung Cancer. IASLC 18th World Conference on Lung Cancer, 2017.
89. Gibbons DL, Byers L, Gerber DE, Peguero J, Micklem D, Yule M, Lorens J. A Ph I/II Study of BGB324, a Selective AXL Inhibitor as Monotherapy and in Combination with Erlotinib in Advanced NSCLC. IASLC 18th World Conference on Lung Cancer, 2017.
90. Gibbons DL, Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Rodriguez-Canales J, Liu X, Huang A, Zhao Q, Peng D, Fradette JJ, Tong P, Ungewiss C, Fan Y, Peng D, Villalobos P, Dmitovsky E, Papadimitrakopoulou VA, Wang J, Byers LA. CD38-Mediated Immunometabolic Suppression as a Mechanism of Resistance to PD-1/PD-L1 Axis Blockade. IASLC 18th World Conference on Lung Cancer, 2017.
91. Byers LA, Golden L, Zhang W, Lin AB, Forster M. A Phase 2 Study of Prexasertib in Patients with Extensive Stage Small Cell Lung Cancer. 2017 ASCO Annual Meeting 12(S1):S570, 2017.
92. Atrafi F, Groen HJM, Byers LA, Garralda E, Lolkema MP, Sangha RS, Ramirez SV, Chae YK, Camidge DR, Gabrail NY, Waskiewicz T, Hu B, Xu T, Nuthalapati S, Hoening E, Komarnitsky P, Blanco AC, Centrum EM. Phase 1/2 Study of Veliparib (V) Combined with Carboplatin (Cb) and Etoposide (E) in Patients (pts) with Extensive-stage Disease (ED) Small Cell Lung Cancer (SCLC) and Other Solid Tumors: Phase 1 Results. 2017 ASCO Annual Meeting, 2017.
93. Byers LA, Krug L, Waqar S, Dowlati A, Hann C, Chiappori A, Owonikoko T, Woo K, Bensman Y, Hurtado B, Cardnell R, Diao L, Fan Y, Fujimoto J, Rodriguez-Canales J, Long L, Sulman E, Wistuba I, Wang J, Travis W, Chen A, Rudin C, Kris M, Fleisher M, Heymach J, Pietanza MC. Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a PHASE II Trial. 2017 ASCO Annual Meeting 12(S1):S207, 2017.
94. Tsao AS, Wistuba II, Xia D, Byers LA, Diao L, Wang J, Papadimitrakopoulou V, Tang XM, Lu W, Kadara H, Gumus ZH, Tan Z, Zhang S, Nilsson MB, Heymach J. Response of Germline and Somatic Smoothened (SMO) Mutations in Non-small Cell Lung Cancer (NSCLC) to Hedgehog Inhibitor Vismodegib. 2017 ASCO Annual Meeting 35(suppl. 15), 2017.
95. Gay CM, Tong P, Cardnell RJ, Su X, Kalu NN, Banerjee U, Bara RO, Johnson FM, Heymach JV, Wang J, Byers LA. Differential Sensitivity Analysis for Resistant Malignancies (DISARM), A Novel Approach for Drug Screen Analysis, Identifies Common Candidate Drugs Across Platinum-resistant Cancer Types. AACR Annual Meeting 2017, 2017.
96. Chen L, Diao L, Yang Y, Yi X, Rodriguez J, Fan Y, Rodriguez L, Fradette J, Ungewiss C, Roybal J, Zhu J, Wang J, Byers LA, Ullrich S, Wistuba I, Heymach J, Qin XF, Gibbons D. CD38 Blockade Overcomes the Immune Resistance to Anti-PD-L1 Therapy by Boosting CD8 T Cell Response. AACR Annual Meeting 2017, 2017.
97. Sen T, Tong P, Diao L, Hong-Fan Y, Stewart CA, Heymach JV, Wang J, Byers LA. WEE1 Inhibitor Activity Correlates to AXL/mTOR Expression and Exhibits Synergy with Temozolomide (TMZ) in Small Cell Lung Cancer (SCLC). AACR Annual Meeting 2017, 2017.
98. Chen L, Byers LA, Ullrich S, Wistuba II, Qin XF, Gibbons DL. CD38 as a Novel Immune Checkpoint and a Mechanism of Resistance to the Blockade of the PD-1/PD-L1 Axis. ASCO-SITC Clinical Immuno-Oncology Symposium, 2017.
99. Gibbons DL, Cardnell RJ, Balaji K, Ungewiss C, Fradette J, Diao L, Tong P, Wang J, Heymach JV, Byers LA. AXL as a Target to Reverse EMT, Treatment Resistance and Immunosuppression. 2016 LUNGevity Science Meeting, 2016.
100. Elamin Y, Xia D, Gold KA, Byers LA, Fan YH, Diao L, Wang J, Giri U, Gudikote J, Tran HT, Heymach J. Reprogramming of Cell Signaling in Response to MEK Inhibition in Non-small Cell Cancer (NSCLC). 2016 ASCO Annual Meeting 34(suppl; abstr e23222), 2016.
101. Rudin CM, Pietanza MC, Bauer TM, Spigel DR, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA, Robert F, Strickland DK, Zayed H, Govindan R, Dylla S, Peng SL. Safety and Efficacy of Single-agent Rovalpituzumab Tesirine (SC16LD6.5), A Delta-like Protein 3 (DLL3)-targeted Antibody-drug Conjugate (ADC) in Recurrent or Refractory Small Cell Lung Cancer (SCLC). 2016 ASCO Annual Meeting 34(suppl; abstr LBA8505), 2016.
102. Pietanza MC, Krug LM, Waqar SN, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo K, Bensman Y, Hurtado B, Fujimoto J, Wistuba II, Travis WD, Chen AP, Heymach J, Kris MG, Fleisher M, Rudin CM, Byers LA. A Multi-center, Randomized, Double-blind Phase II Study Comparing Temozolomide (TMZ) Plus either Veliparib (ABT-888), a PARP Inhibitor, or Placebo as 2nd or 3rd-line Therapy for Patients (Pts) with Relapsed Small Cell Lung Cancers (SCLCs). 2016 ASCO Annual Meeting 34(suppl; abstr 8512), 2016.
103. Skinner HD, Giri U, Story MD, Wang J, Shen L, Yoo SY, Byers LA, Pickering CR, Myers J, Williams MD, Heymach J. Proteomic and mRNA Expression Analysis Identifies PDL-1 Expression as a Marker of Treatment Failure in Head and Neck Cancer. 2016 ASCO Annual Meeting 34(suppl; abstr 6042), 2016.
104. Tran HT, Elamin Y, Simon GR, Blumenschein GR, Tsao AS, Papadimitrakopoulou V, Gibbons DL, Fossella FV, Lanman RB, Banks KC, Byers LA, Zhang J, Heymach J. Clinical Utilization of a CLIA-certified Cell-free DNA (cfDNA) Blood Test for Identification of Targetable Molecular Alterations in Patients with Non-small Cell Lung Cancer (NSCLC). 2016 ASCO Annual Meeting 34(suppl; abstr e23064), 2016.
105. Sen S, Rao A, Janku F, Hong DS, Tsimberidou AM, Piha-Paul SA, Heymach J, Byers LA, Meric-Bernstam F, Subbiah V. Co-occurring Genomic Alterations and Association with Progression Free Survival in BRAFV600 Mutated Non-melanoma Tumors Treated with BRAF Inhibitor. 2016 ASCO Annual Meeting 34(suppl; abstr 2546), 2016.
106. Tang H, Zhang J, Hu X, Xu Y, Dong B, Kong Y, Zhang X, Liao ZX, Zhang J, Byers LA, Gibbons DL, Glisson BS, Wistuba II, Heymach J, Gomez DR, Futreal A, Chen M. Preliminary Analysis of Genomic Profiling of Small Cell Lung Cancer in Chinese Population Revealed Frequent PIK3CA Hotspot Mutations. 2016 ASCO Annual Meeting 34(suppl; abstr e20089), 2016.
107. Gay CM, Kundu S, Diao L, Glisson B, Wang J, Heymach JV, Byers LA, Gibbons DL. Unique microRNA Signatures in Small Cell Lung Cancer Correlate with Distinct Protein Expression Profiles and Drug Response. AACR Annual Meeting 2016, 2016.
108. Sen T, Tong P, Wang J, Byers LA. Proteomic Profiling Identifies ATM Expression Level as a Predictive Biomarker to ATR and PARP Inhibition in Small Cell lung Cancer (SCLC). AACR Annual Meeting 2016, 2016.
109. Denning WL, Skoulidis F, Shen L, Papadimitrakopoulou V, Diao L, Lou Y, Byers LA, Wang J, Canales JR, Wistuba II, Weinstein J, Gibbons DL, Heymach JV. Loss of LKB1 Mediates an Immune Inert Phenotype in Human Lung Adenocarcinoma. AACR Annual Meeting 2016, 2016.
110. Cardnell RJ, Li L, Masrorpour F, Niu H, Ecsedy J, Wang J, Byers LA. Proteomic Profiling Identifies cMyc and TTF1 as Biomarkers of Response to the Aurora Kinase Inhibitor Alisertib in Small Cell Lung Cancer (SCLC). AACR Annual Meeting 2016, 2016.
111. Kalu NN, Mazumdar T, Tong P, Shen L, Wang J, Byers LA, Johnson FM. Cell-based, High-throughput Screen for Small Molecule Inducers of Cell Death in HPV-associated Head and Neck Cancers. AACR Annual Meeting 2016, 2016.
112. Sambandam V, Shen L, Zhang M, Saigal R, Tong P, Mazumdar T, Byers LA, Pickering C, Myers JN, Wang J, Johnson FM, Frederick M. NOTCH1 Inactivating Mutation Mediates Sensitivity to PI3K/mTOR Inhibitors in Head and Neck Squamous Cell Carcinoma. AACR Annual Meeting 2016, 2016.
113. Stewart C, Tong P, Cardnell R, Masrorpou F, Wang J, Byers LA. SLFN11 is a Biomarker of Sensitivity to PARP Inhibition and Chemotherapy in Small Cell Lung Cancer (SCLC). AACR Annual Meeting 2016, 2016.
114. Sen T, Tong P, Stewart A, Cristea S, Fan YH, Glisson BS, Gibbons DL, Sage J, Wang J, Byers LA. Exploiting the G2-M Cell Cycle Checkpoint Dependency in Small Cell Lung Cancer (SCLC) using Pharmacological Inhibitors of CHK1 and WEE1. AACR The Cancer Cell Cycle: Tumor Progression and Therapeutic Response, 2016.
115. Sen T, Chen L, Rodriguez BL, Yang Y, Hong-Fan Y, Stewart CS, Glisson B, Piwnica-Worms H, Sage J, Heymach JV, Gibbons DL, Byers LA. Combining Immune Checkpoint Targeting and DNA Damage Repair (DDR) Targeted Therapy in Small Cell Lung Cancer (SCLC). AACR Special Conference AACR Conference on Tumor Immunology and Immunotherapy, 2016.
116. Sen T, Tong P, Stewart CA, Fan YH, Feng Y, Wang J, Byers LA. Investigation of Chk1 as a Novel Therapeutic Target for Small Cell Lung Cancer (SCLC). 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, 2015.
117. Feng Y, Yu K, Cardnell RJ, Ru Y, Wang E, Wang J, Post LE, Byers LA, Shen Y. Talazoparib Predictive Biomarker Analysis in Human Small Cell Lung Cancer Cells and PDX Tumors. 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, 2015.
118. Lou Y, Diao L, Cuentas ERP, Denning W, Chen L, Fan Y, Rodriguez J, Byers L, Wang J, Papadimitrakopoulou V, Behrens C, Wistuba I, Hwu P, Heymach JV, Gibbons DL. EMT is Associated with an Inflammatory Tumor Microenvironment. IASLC 16th World Conference on Lung Cancer, 2015.
119. Skoulidis F, Byers LA, Tong P, Diao L, Denning W, Gudikote J, Fan Y, Papadimitrakopoulou V, Izzo JG, Behrens C, Kadara H, Cuentas ERP, Rodriguez-Canales J, Gibbons DL, Weinstein JN, Girard L, Minna J, Wang J, Wistuba I, Heymach JV. Landscape and Functional Significance of KRAS Co-Mutations in Lung Adenocarcinoma (LUAC). IASLC 16th World Conference on Lung Cancer, 2015.
120. Mak MP, Diao L, Tong P, Wang J, Ng PK, Cardnell RJ, Hayes DN, Robertson G, Myers JN, El-Naggar A, William WN, Coombes KR, Weinstein JN, Mills GB, Heymach JV, Gibbons DL, Byers LA. Enriched Expression of PD-L1 and Other Immune Targets after Epithelial-mesenchymal Transition (EMT) in Squamous Head and Neck and Lung Cancers. 2015 ASCO Annual Meeting, 2015.
121. Denning WL, Diao L, Skoulidis F, Lou Y, Byers LA, Wang J, Weinstein J, Gibbons DL, Heymach JV. Defined Co-mutation Subgroups of KRAS-mutated NSCLC Display Distinct Immune Profiles. AACR Annual Meeting 2015, 2015.
122. Sambandam C, Shen L, Zhang M, Saigal R, Byers LA, Pickering C, Myers JN, Wang J, Johnson FM. Integrative Drug Sensitivity Analysis of PI3K /mTOR Pathway Inhibitors in Head and Neck Squamous Cell Carcinoma (HNSCC). AACR Annual Meeting 2015, 2015.
123. Valliani AA, Sen T, Masrorpour F, Diao L, Cardnell RJ, Wang J, Glisson BS, Piwnica-Worms H, Gibbons DL, Byers LA. Check Point Kinase 1 (Chk1) Targeting as a Novel Therapeutic Strategy in Small Cell Lung Cancer (SCLC). AACR Annual Meeting 2015, 2015.
124. Shelly J, Cardnell RJ, Masrorpour F, Diao L, Wang J, Byers LA. PARP and Bcl-2 Co-inhibition in Small Cell Lung Cancer (SCLC). AACR Annual Meeting 2015, 2015.
125. Mukherjee S, Mitani Y, Cardnell RJ, Fan YH, Diao L, Wang J, El-Naggar AK, Byers LA. Comprehensive Proteomic Analysis of Salivary Gland Cancer Subtypes. AACR Annual Meeting 2015, 2015.
126. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou V, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Rodriguez-Canales J, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan YH, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GM, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occurring Genomic Alterations Define Major Subsets of KRAS-mutant Lung Adenocarcinoma (LUAC) with Distinct Biology and Therapeutic Vulnerabilities. AACR Annual Meeting 2015, 2015.
127. Mukherjee S, Glisson BS, Minna JD, Cardnell RJ, Girard L, Gazdar A, Diao L, Wang J, Byers LA. Characterization of Methylation Profiles Reveals Distinct Epigenomic Patterns in SCLC and NSCLC. AACR Annual Meeting 2015, 2015.
128. Balaji K, Cardnell R, Diao L, Tong P, Mak M, Fan YH, Masrorpour F, Warner SL, Bearss DJ, Wistuba II, Mills GB, Heymach JV, Keyomarsi K, Wang J, Byers LA. Identification of Biomarkers of AXL-mediated Drug Resistance in Head and Neck Squamous Cell Carcinoma. AACR Annual Meeting 2015, 2015.
129. Peng DH, Tong P, Byers LA, Wang J, Creighton CJ, Gibbons DL. Zeb1 Induces LOXL2-mediated Collagen Stabilization and Deposition in the Extracellular Matrix to Drive Lung Cancer Invasion and Metastasis. AACR Tumor Metastasis:52, 2015.
130. Cardnell RJ, Feng Y, Diao L, Fan Y, Masrorpour F, Mukherjee S, Shen J, Wang J, Byers LA. Modulation of PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer. 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 2014.
131. Cardnell RJ, Behrens C, Diao L, Fan Y, Tang X, Minna JD, Mills GB, Heymach JV, Wistuba II, Wang J, Byers LA. An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-negative Tumors. 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 2014.
132. Feng Y, Post LE, Cardnell RJ, Byers LA, Wang B, Shen Y. BMN 673 as Single Agent and in Combination with Temozolomide or PI3K Pathway Inhibitors in Small Cell Lung Cancer and Gastric Cancer Models. 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 2014.
133. Mak MP, Tong P, Diao L, Ng PKS, Fan Y, Cardnell RJ, Gibbons DL, William WN, Heymach JV, Coombes KR, Byers LA, Wang J. A Pan-cancer Tumor-derived Epithelial-to-mesenchymal Transition (EMT) Signature Determines Patterns of Drug Sensitivity and Enrichment in Immune Target Expression following EMT. 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 2014.
134. Wainberg ZA, Rafii S, Ramanathan RK, Mina LA, Byers LA, Chugh R, Goldman JW, Sachdev JC, Matei DE, Wheler JJ, Henshaw JW, Zhang C, Gallant G, De Bono JS. Safety and Antitumor Activity of the PARP Inhibitor BMN673 in a Phase 1 Trial Recruiting Metastatic Small-cell Lung Cancer (SCLC) and Germline BRCA-mutation Carrier Cancer Patients. 2014 ASCO Annual Meeting, 2014.
135. Lou Y, Diao L, Byers LA, Gibbons DL, Denning W, Wang J, Papadimitrakopoulou V, Wistuba II, Goswami S, Cortez MA, Welsh J, Kurie JM, Heymach JV. Association of Epithelial-mesenchymal Transition Status with PD1/PDL1 Expression and a Distinct Immunophenotype in Non-small Cell Lung Cancer: Implications for Immunotherapy Biomarkers. 2014 ASCO Annual Meeting, 2014.
136. Byers LA, Diao L, Ng PK, Heymach C, Fan YH, El-Naggar AK, Wang J, Mills GB, Johnson FM. Proteomic Profiling of HPV-positive Head and Neck Cancer to Identify New Candidates for Targeted Therapy. 2014 ASCO Annual Meeting, 2014.
137. Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Heymach JV, Kalhor N, Gupta S, Gettinger SN, Byers LA, Izzo J, Miller VA, Diao L, Wang J, Wei C, Coombes KR, Mauro DJ, Rubin EH, Hong WK, Herbst RS. BATLLE-2: KRAS Mutation and Outcome in a Biomarker-integrated Study in Previously Treated Patients (pts) with Advanced Non-small Cell Lung Cancer (NSCLC). 2014 ASCO Annual Meeting, 2014.
138. Gibbons DL, Chen L, Goswami S, Cortez MA, Ahn YH, Byers LA, Lin W, Diao L, Wang J, Roybal J, Ungewiss C, Antonia SJ, Mediaville-Varela M, Suraokar MB, Welsh J, Chen L, Wistuba II, Heymach JV, Kurie JM, Qin XF. Regulation of Tumor Cell PD-L1 Expression by MicroRNA-200 and Control of Lung Cancer Metastasis. 2014 ASCO Annual Meeting, 2014.
139. Yang C, Cortez MA, Giri U, Gudikote J, Wierda WG, Gandhi V, Byers LA, Heymach JV. NSCLC Cells with LKB1 Mutation are Vulnerable to Energetic and Oxidative Stresses Induced by 8-Chloroadenosine. AACR Annual Meeting 2014, 2014.
140. Cortez MA, Yang C, Byers LA, Diao L, Allen T, Giri U, Wang J, Welsh J, Heymach JV. Reciprocal Regulation of MYC and LKB1 Modulates Cell Survival and Differentiation in Lung Cancer. AACR Annual Meeting2014, 2014.
141. Sen B, Peng S, Mazumdar T, Byers LA, Kadara H, Johnson FM. The Multitargeted Kinase Inhibitor Dasatinib Induces DNA Damage, Hippo Pathway Engagement and Senescence in Lung Cancer Cell Lines that Possess Kinase-inactivating BRAF Mutations. AACR Annual Meeting 2014, 2014.
142. Heymach JV, Diao L, Byers LA, Nilsson M, Wang J, Cortez MA. Tumor Suppressor miR-339-5p Regulates PD-L1 Expression in Lung Cancer. AACR Annual Meeting 2014, 2014.
143. Mazumdar T, Byers LA, Ng PK, Mills GB, Peng S, Diao L, Fan YH, Stemke-Hale K, Heymach JV, Myers JN, Glisson BS, Johnson FM. Evaluation of Predictive Biomarkers and Resistance Mechanisms of PI3K Pathway Inhibition in Head and Neck Squamous Cell Carcinoma. AACR Annual Meeting 2014, 2014.
144. Tong P, Mak MP, Diao L, Wang J, Ng PK, Fan YH, Jr WW, Heymach JV, Coombes KR, Byers LA. An Integrated Analysis of EMT Across Diverse Cancer Types Identifies New Potential Therapeutic Targets. AACR Annual Meeting 2014, 2014.
145. Xia D, Byers LA, Diao L, Wang J, Lin SH, Gibbons DL, Gold KA, Paul J, Liu N, Heymach JV. Integrated Genomic and Proteomic Analysis Identifies PTEN Loss and AKT/MTOR as Drivers of Resistance to MEK Inhibitors in NSCLC Cells. AACR Annual Meeting 2014, 2014.
146. Skoulidis F, Coombes KR, Diao L, Tong P, Cortez MA, Giri U, Yang C, Fan YH, Weinstein JN, Papadimitrakopoulou V, Minna JD, Wang J, Byers LA, Heymach JV. Co-mutations Define Major Subsets of KRAS-driven Lung Adenocarcinoma with Implications for Targeted Cancer Therapy. AACR Annual Meeting 2014, 2014.
147. Gibbons DL, Chen L, Goswami S, Ahn YH, Byers LA, Diao L, Wang J, Cortez A, Roybal J, Welsh J, Zhang X, Dwyer D, Yi X, Lieping C, Wistuba II, Heymach JV, Kurie JM, Qin FX. MicroRNA-200 Regulates Tumor Cell PD-L1 Expression to Control Lung Cancer Metastasis. AACR-IASLC Joint Conference on The Molecular Origins of Lung Cancer, 2014.
148. Mina LA, Waiberg ZA, Ramanathan RK, Byers LA, Chugh R, Zhang C, Henshaw JW, Dorr A, Rafii S, Sachdev J, Glaspy J, de Bono JS. Update on First-in-human Trial of Novel PARP Inhibitor BMN 673 in Patients with Solid Tumors. 2013 San Antonio Breast Cancer Symposium, 2013.
149. Wainberg ZA, de Bono JS, Mina L, Sachdev J, Byers LA, Chugh R, Zhang C, Henshaw JW, Dorr A, Glaspy J, Ramanathan R. Update on First-in-man Trial of Novel Oral PARP Inhibitor BMN 673 in Patients with Solid Tumors. 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, 2013.
150. Mak MP, Valliani A, Cardnell RJ, Bailey AM, Eterovic AK, Zhao H, Chen K, Wistuba II, Meric-Bernstam F, Mills GB, Byers LA, Gibbons DL. Molecular Evolution of Lung Adenocarcinoma in a Young Never-smoker Patient. 2013 Symposia on Cancer Research, 2013.
151. Skoulidis F, Diao L, Fan YH, Minna JD, Weinstein JN, Wang J, Heymach JV, Byers LA. Impact of Co-occurring Genetic Events on the Signaling Landscape of KRAS-mutant Lung Adenocarcinoma. IASLC 15th World Conference on Lung Cancer (WCLC 2013), 2013.
152. Gold KA, Byers LA, Xia D, Fan YH, Diao L, Groth P, Paul J, Wang J, Giri U, Gudikote J, Tran HT, Coombes KR, Minna JD, Liu N, Heymach JV. Proteomic Analysis Identifies Baseline PI3K/Akt Pathway Activation and Treatment-induced Suppression of mTOR Signaling as Determinants of Response to MEK Inhibition. IASLC 15th World Conference on Lung Cancer (WCLC 2013), 2013.
153. Diao L, Tong P, Wang J, Fan YH, Liu Y, Liu W, Behrens C, Wistuba II, Heymach JV, Weinstein JN, Mills GB, Byers LA. An Integrated Proteomic Analysis of Lung Adenocarcinomas from The Cancer Genome Atlas (TCGA) Reveals Potential Targets for Oncogene-negative Tumors. 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, Boston, Massachusetts, 2013.
154. Byers LA, Diao L, Wang J, Gibbons DL, Robertson G, Cardnell RJ, Masrorpour F, Fan YH, Rodriguez J, Tang X, Weinstein JN, Minna JD, Wistuba II, Mills GB, Heymach JV. Targeting EMT in Lung Cancer: An Integrated Analysis of Axl and Other Mesenchymal Targets in the Cancer Genome Atlas (TCGA). IASLC 15th World Conference on Lung Cancer (WCLC 2013), 2013.
155. Mak MP, Diao L, Wang J, Ng PK, Fan YH, Story MD, William WN JR, Heymach JV, Weinstein JN, Coombes KR, Byers LA. Identification of Candidate Therapeutic Targets in Mesenchymal Head and Neck Squamous Cell Carcinoma. 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, 2013.
156. Ferrarotto R, Suryavanshi M, Yoo SY, Wang J, Byers LA, Glisson BS, Heymach JV, Johnson FM. Identifying Biomarkers of Sensitivity to Polo-like Kinase Inhibitors (Plki) in Non-small-cell Lung Cancer (NSCLC). 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, 2013.
157. Ramanathan RK, Wainberg ZA, Mina LA, Byers LA, Chugh R, Zhang C, Henshaw JW, Dorr A, de Bono J. PARP Inhibition with BMN 673 in Ovarian and Breast Cancer Patients with Deleterious Mutations of BRCA1 and BRCA2. 17th ECCO-38th ESMO-32nd ESTRO European Cancer Congress, 2013.
158. Gold KA, Byers LA, Fan YH, Fujimoto J, Tse WH, Lee JJ, Gupta S, Wistuba II, Stewart DJ, Gibbons DL. A Phase I/II trial Combining Erlotinib with Gamma Secretase Inhibitor RO4929097 in Advanced Non-small Cell Lung Cancer (NSCLC). 2013 ASCO Annual Meeting, 2013.
159. De Bono JS, Mina LA, Gonzalez M, Curtin NJ, Wang E, Henshaw JW, Chadha M, Sachdev JC, Matei D, Jameson GS, Ong M, Basu B, Wainberg ZA, Byers LA, Chugh R, Dorr A, Kaye SB, Ramanathan RK. First-in-human Trial of Novel Oral PARP inhibitor BMN 673 in Patients with Solid Tumors. 2013 ASCO Annual Meetin, 2013.
160. Cardnell R, Diao L, Wang J, Bearss D, Warner S, Fan YH, Giri U, Story MD, Weinstein JN, Coombes KR, Williams MD, Wistuba II, Mills GB, Myers J, William WN, Ang KK, Heymach J, Byers LA. An Epithelial-mesenchymal Transition (EMT) Gene Signature to Predict Resistance to EGFR Inhibition and AXL Identification as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma. 2013 ASCO Annual Meeting, 2013.
161. Cortez MA, Byers LA, Fan YH, Diao L, Groth P, Paul J, Wang J, Giri U, Gudikote J, Tran HT, Coombes K, Minna JD, Liu N, Heymach JV. Proteomic Analysis Reveals Src/Stat and EGFR/MAPK Pathways as Potential Mechanism of Resistance to PI3K Inhibitors in Lung Cancer. AACR Annual Meeting 2013, 2013.
162. Cardnell RJ, Feng Y, Diao L, Fan YH, Wang J, Shin Y, Minna JD, Heymach JV, Byers LA. Proteomic Profiling Identifies PI3K and DNA Repair Pathways as Potential Markers of Response to PARP Inhibitor BMN673 in SCLC. AACR Annual Meeting 2013, 2013.
163. Gold KA, Byers LA, Fan YH, Diao L, Groth P, Paul J, Wang J, Giri U, Gudikote J, Tran H, Coombes KR, Minna JD, Liu N, Heymach JV. Proteomic Analysis of Effects of MEK Inhibition with BAY86-9766 on LKB1/AMPK and mTOR Pathway in Lung Cancer Cell Lines. AACR Annual Meeting 2013, 2013.
164. Byers LA, Horn L, Gandhi J, Kloecker G, Owonikoko TK, Waqar S, Krzakowski MJ, Choy G, Cecchettini N, Taverna P, Sahai A, Noursalehi M, Azab M, Camidge DR. A Phase 2 Study of Amuvatinib (MP-470), the First RAD51 Inhibitor in Combination with Platinum-etoposide (PE) in Refractory or Relapsed Small Cell Lung Cancer (ESCAPE). AACR Annual Meeting 2013, 2013.
165. Gibbons DL, Ungewiss C, Peng DH, Rizvi ZH, Byers LA, Robertson G. MicroRNA-200 Controls Matrix Deposition and Matrix-dependent SRC Signaling to Produce Tumor Cell Invasion. Cold Spring Harbor Laboratory, 2013.
166. Mazumdar T, Byers LA, Peng S, Diao L, Hale KS, Glisson BS, Johnson FM. Genetic Determinants of Sensitivity and Resistance to PI3K Inhibitors in Head and Neck Cancers for Efficient Targeted Therapy. AACR Annual Meeting 2013, 2013.
167. Byers LA, Cortez MA, Yang C, Wang J, Diao L, Fan YH, Girard L, Gazdar A, Wistuba I, Minna JD, O'Connor M, Barr S, Heymach JV. Proteomic Profiling of Signaling Pathways in LKB1 Deficient Non-small Cell Lung Cancers (NSCLC) Identifies Novel Therapeutic Targets Including IGF1R Pathway. AACR Annual Meeting 2013, 2013.
168. Yang C, Giri U, Cortez MA, Gudikote J, Fan Y, Diao L, Byers LA, Heymach JV. LKB1 Overexpression Regulates DNA Repair Pathway and Sensitivity to Radiation in LKB1 Mutant Non-small Cell Lung Cancer Cell Lines. AACR Annual Meeting 2013, 2013.
169. Atlas Network TCG, Working Group LAA, Meyerson M. Comprehensive Analysis of Lung Adenocarcinoma. The Cancer Genome Atlas', 2nd Annual Scientific Symposium, 2012.
170. Byers LA, Nilsson MB, Masrorpour F, Wang J, Diao L, Bhardwaj V, Welsh J, Girard L, Coombes KR, Weinstein JN, Lippman SM, Glisson BS, Minna JD, Heymach J. Investigation of PARP1 as a Therapeutic Target in Small Cell Lung Cancer. 2012 ASCO Annual Meeting, 2012.
171. Yilmaz E, Byers LA, Diao L, Giri U, Gudikote J, Fan YH, Wang J, Coombes KR, Girard L, Minna JD, Heymach J. Use of Proteomic Analysis of LKB1/AMPK/mTOR Pathways to Identify IGF-1R Pathway Upregulation with LKB1 Loss or mTOR Inhibition in NSCLC: Implications for Targeted Combinations. 2012 ASCO Annual Meeting, 2012.
172. Dai B, Liu W, Heymach JV, Byers LA, Wang J, Coombes KR, Fang B, Roth JA. Identify Signaling Responses to MEK Inhibitor AZD6244 in Lung Cancer Cells with Proteomics Reverse Phase Protein Array. AACR Annual Meeting 2012, 2012.
173. Cortez MA, Bhardwaj V, Zhan Y, Calin GA, Byers LA, Heymach JV, Welsh JW. MiR-200c Overexpression Radiosensitizes Lung Cancer Cells. AACR Annual Meeting 2012, 2012.
174. Byers LA, Diao L, Wang J, Girard L, Peyton M, Gazdar A, Groth P, Paul J, Liu N, Kim ES, Mauro D, Herbst RS. LKB1 and KRAS Mutations Predict Resistance to PI3K/Akt Inhibitors in Non-small Cell Lung Cancer. AACR Annual Meeting 2012, 2012.
175. Zhang J, Giri U, Cantu K, Wang J, Beketaev I, Byers LA, Saintigny P, Heymach JV, Lin SH. Casitas B-lineage Lymphoma-3 is an Epigenetically Regulated Gene whose Knockdown Induces Mesenchymal to Epithelial Transition and Enhances Erlotinib Sensitivity in Lung Cancer Cell Lines. AACR Annual Meeting 2012, 2012.
176. Bhardwaj V, Likhacheva A, Byers LA, Diao L, Allen PK, Minna JD, Ihle NT, Powis G, Das AK, Girard L, Peyton M, Yordy J, Liao Z, Ang KK, Story M, Kalhor N, Komaki R, Kim ES, Heymach JV, Welsh JW. Establishing Role of KRAS Mutation on NSCLC Radio-sensitivity. AACR Annual Meeting 2012, 2012.
177. Byers LA, Wang J, Diao L, Girard L, Peyton M, Coombes K, Weinstein JN, Gandi V, Krett N, Rosen ST, Minna JD, Heymach JV. An Epithelial to Mesenchymal Transition (EMT) Gene Expression Signature Predicts Resistance to PI3K/Akt Pathway Inhibitors in Non-small Cell Lung Cancer. 2011 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, 2011.
178. Byers LA, Nilsson M, Fujimoto J, Santigny P, Wang J, Diao L, Peyton M, Y-H F, Giri U, Weber S, Duchemann B, Girard L, Coombes K, Weinstein J, Minna JD, Wistuba I, Heymach JV. Investigation of PARP1 as a Novel Therapeutic Target in Small Cell Lung Cancer. 14th World Conference on Lung Cancer, 2011.
179. He Y, Zhou Z, Hofstetter WL, Zhou Y, Hu W, Pataer A, Correa AM, Lu Y, Wang J, Diao L, Byers LA, Wistuba I, Roth JA, Swisher SG, Heymach JV, Fang B. Aberrant Signal Transduction and DNA Damage Response Pathways in Primary Lung Cancer. 14th World Conference on Lung Cancer, 2011.
180. Heymach JV, Saintigny P, Kim ES, Byers LA, Lee JJ, Coombes K, Diao L, Wang J, Tran H, Fan YH, Tsao A, Blumenschein Jr GR, Papadimitrakopoulou VA, Tang X, Story M, Xie Y, Girard L, Weinstein J, Mao L, Minna JD, Herbst RS, Lippman SM, Hong WK, Wistuba II. Gene Expression Signatures Predictive of Clinical Outcome and Tumor Mutations in Refractory NSCLC Patients (pts) in the BATTLE Trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination). AACR Annual Meeting 2011, 2011.
181. Riquelme EM, Suraokar MB, Nunez MI, Gazdar AF, Byers LA, Heymach JV, Mehran RJ, Tsao A, Wistuba II. CNG c-myc in Mesothelioma. AACR Annual Meeting 2011, 2011.
182. Byers LA, Wang J, Yordy J, Fan YH, Giri U, Shen L, Diao L, Liu W, Wistuba I, Girard L, Coombes K, Weinstein J, Minna J, Heymach J. Identification of Signaling Pathways Active in Small Cell Lung Cancer Compared to Non-small Cell Lung Cancer by Proteomic Profiling. Cancer Prevention and Research Institution of Texas (CPRIT), 2010.
183. Wang J, Lin SH, Yordy J, Byers LA, Diao, L, Weinstein J, Coombes K, Minna J, Heymach JV. Integrative Analysis of DNA Methylation and Gene Expression Identifies a DNA Methylation Signature Associated with Erlotinib Resistance in EGFR Wild Type Non-Small Cell Lung Cancer Cells. 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 2010.
184. Byers LA, Wang J, Diao L, Yordy J, Girard L, Story M, Coombes K, Weinstein J, Minna J, Heymach J. An Epithelial to Mesenchymal Transition (EMT) Gene Expression Signature Identifies Axl as an EMT Marker in Non-small Cell Lung Cancer (NSCL) and Head and Neck Cancer (HNC) Lines and Predicts Response to Erlotinib. 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 2010.
185. Ihle NT, Kingston J, Gumbiner-Russo L, Byers LA, Yordy J, Giri U, Heymach JV, Minna J, Larsen J, Herbst R, Garth P. KRas Mediated Induction of HIF-1α in Normoxia Promotes Tumorigenesis and Identifies HIF-1α as a Therapeutic Target. AACR Annual Meeting, 2010.
186. Byers LA, Wang J, Yordy J, Fan Y, Giri U, Shen L, Wistuba I, Girard L, Coombes K, Weinstein J, Minna J, Heymach J. Identification of Signaling Pathways Active in Small Cell Lung Cancer (SCLC) Compared to Non-small Cell Lung Cancer (NSCLC) by Proteomic Profiling. AACR Annual Meeting 2010, 2010.
187. Saintigny P, Byers LA, Zhang L, Yordy J, Tang XM, Girard L, Lang W, Fan YH, Ji L, Lee J, Kim ES, Hong WK, Lippman SM, Herbst RS, Minna J, Wistuba II, Heymach JV, Mao L. MYC Downregulation and Chemorisistance in Non-small Cell Lung Cancer (NSCLC): Evidence from the Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) Program. AACR Annual Meeting 2010, 2010.
188. Yordy JS, Giri U, Wang J, Molkentine D, Raju U, Coombes K, Byers LA, Ang K, Heymach J, Story MD. Use of Genome-wide Transcript Profiling to Identify Genes Associated with Radiation Response in Head and Neck Squamous Cell Carcinoma Cell Lines. 2010 ASCO-NCI-EORTC Molecular Markers Meeting, 2010.
189. Lin SH, Wang J, Diao L, Yordy JS, Byers LA, Weinstein J, Coombes K, Girard L, Minna JD, Heymach J. Use of Integrative Analysis of DNA Methylation and Gene Expression Profiles to Identify Epigenetic Regulation of Genes Associated with Epithelial-mesenchymal Transition (EMT). 2010 ASCO-NCI-EORTC Molecular Markers Meeting, 2010.
190. Saintigny P, Zhang L, Girard L, Byers LA, Lam D, Beer D, Tsao M, Wistuba I, Minna J, Heymach J. Use of an EGFR Mutation Signature to Estimate Prognosis in EGFR Wild-type Lung Adenocarcinomas and Identify Metastasis Associated in Colon Cancer 1 (MACC1) as a Regulator of MET. 2010 ASCO-NCI-EORTC Molecular Markers Meeting, 2010.
191. Byers LA, Heymach JV, Lee JJ, Lin H, El-Naggar AK, Papadimitrakopoulou V, Lippman SM, Hong WK, Holsinger FC, Kies MS. Association between Human Papilloma Virus (HPV) Status with Serum Cytokine and Angiogenic Factor (CAF) Profile after Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). ASCO Annual Meeting 2009, 2009.
192. Byers LA, Sen B, Saigal B, Nanjundan M, Mills G, Heymach J, Johnson F. Reciprocal Regulation of Src and STAT3 Activation in Non-small Cell Lung Cancer. AACR Annual Meeting 2009, 2009.
193. Byers LA, Tran HT, Tumula PK, Yan S, Du Z, Herynk M, Minna JD, Heymach JV. Use of Cytokine and Angiogenic Factor (CAF) Profiling of Non-small Cell Lung Cancer Cell Lines to Identify Secreted Proteins Associated with Response to Chemotherapy and Targeted Agents. 2008 ASCO-NCI-EORTC Molecular Markers Meeting, 2008.
194. Byers LA, Kies MS, William WN, Hu J, Lee JJ, El-Naggar A, Papadimitrakopoulou V, Myers JN, Lippman SM, Heymach JV. Profiling of Cytokines and Angiogenic Factors (C/AF) in Head and Neck (HN) Cancer Correlates Circulating Biomarkers with Clinical Outcomes following Induction Chemotherapy. ASCO Annual Meeting 2008, 2008.
195. Byers LA, Nanjundan M, Girard L, Coombes K, Xie Y, Peyton M, Zachariah S, Weber S, Siwak D, Nikolinakos P, Wistuba I, Roth J, Mills G, Minna J, Heymach J. Reverse-phase Protein Array (RPPA) Profiling of Response to Taxanes and Epidermal Growth Factor Receptor (EGFR) Inhibitors Identifies an Inverse Correlation between Markers of Sensitivity to Docetaxel and Erlotinib in Non-small Cell Lung Cancer Lines. AACR Annual Meeting 2008, 2008.
196. Yordy JS, Byers LA, Davies M, Mills GB, Ju Z, Raju U, Ang K, Heymach JV. 2008 ASCO-NCI-EORTC Molecular Markers Meeting, 2008.
197. Yordy JS, Byers LA, Davies M, Molkentine D, Nanjundan M, Raju U, Mills G, Minna J, Coombes K, Ang KK, Heymach JV. Reverse Phase Protein Arrays Reveal Biomarkers of Radiation Sensitivity and Resistance in Head and Neck and Lung Cancer Cell Lines. ASTRO Translational Advances in Radiation Oncology and Cancer Imaging Symposium, 2008.
198. Byers LA, Nanjundan M, Girard L, Coombes KR, Xie Y, Peyton M, Ma Y, Zachariah S, Nikolinakos P, Cigarroa R, Mills GB, Roth JA, Minna JD, Heymach JV. Reverse-phase Protein Array (RPPA) Profiling of Non-small Cell Lung Cancer Lines Identifies Tumor Signatures for Sensitivity and Resistance to Chemotherapy and Targeted Agents. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007, 2007.
199. Xi Y, Stewart C, Diao L, Wang Q, Shen L, Wang R, Duarte A, Halliday A, Ramkumar K, Cardnell RJ, Zhang B, Gay CM, Byers LA, Wang J. Inferring Transcriptomic Programs from Circulating Tumor DNA Methylation Signatures in Small Cell Lung Cancer Using RRBS and EM-seq. AACR Annual Meeting 2026.
200. Gray JH, Ramkumar K, Stewart C, Wang R, Duarte A, Tanimoto A, Cardnell RJ, Byers LA, Gay CM. HER2- and TROP2-Antibody-Drug Conjugates in Small Cell Lung Cancer Cell Lines and 3D Culture: Efficacy and Role of Target Expression. AACR Annual Meeting 2026.

Book Chapters

1. Glisson BS, Byers LA, Gay CM. Large cell neuroendocrine carcinoma of the lung. In: UpToDate - Wolters Kluwer Health, 2022.
2. Byers LA. Handbook of Targeted Cancer Therapy. In: Lung Cancer (Non-Small Cell). Wolters Kluwer, 36-39, 2015.
3. Byers LA. Molecular Profiling. In: Lung Cancer. Wiley-Blackwell, 2014.
4. Glisson BS, Byers LA. Pathobiology and Staging of Small Cell Carcinoma of the Lung. In: UpToDate - Wolters Kluwer Health, 2014.
5. Byers LA, Karp DD. Organ Sites – Lung Cancer. In: The Handbook of Targeted Cancer Therapy, 1st edition. Lippincott Williams & Wilkins division of Wolters Kluwer Health Inc., a Delaware Corporation, 2014.
6. Byers LA, Heymach JV. Small Cell Lung Cancer: Treatment of Extensive-stage Disease. In: Lung Cancer, 2013.
7. Byers LA, Kies M. Targeted Therapy in Head and Neck Malignancies. In: Targeted Therapy for Solid Tumors and Hematologic Malignancies -Nova Medical, 2011.
8. Averett L, Salvatori R. Inpatient Management of Endocrinologic Disorders. In: The Osler Medical Handbook. Mosby, 2006.
9. Averett L, Wang D, Juperman D, Rahman J. ECG Interpretation. In: The Osler Medical Handbook. Mosby, 2006.

Books (edited and written)

1. Glisson BS, Byers LA. Pathobiology and Staging of Small Cell Carcinoma of the Lung. UpToDate, 2014.
2. Byers LA. Master's Dissertation, 2003.

Web Publications

1. Byers LA. How are targeted therapies used in lung cancer treatment?, 2024.